BioSig (BSGM) 10-K 31 Mar 22 2021 FY Annual report Financial data

Document And Entity Information

Document And Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2021	Mar. 30, 2022	Jun. 30, 2021
Document Information Line Items
Entity Registrant Name	BIOSIG TECHNOLOGIES, INC.
Trading Symbol	BSGM
Document Type	10-K
Current Fiscal Year End Date	--12-31
Entity Common Stock, Shares Outstanding		38,424,059
Entity Public Float			$ 108,511,450
Amendment Flag	false
Entity Central Index Key	0001530766
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Filer Category	Non-accelerated Filer
Entity Well-known Seasoned Issuer	No
Document Period End Date	Dec. 31, 2021
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	FY
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
ICFR Auditor Attestation Flag	false
Document Transition Report	false
Document Annual Report	true
Entity File Number	001-38659
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	26-4333375
Entity Address, Address Line One	55 Greens Farms Road, 1st Floor
Entity Address, City or Town	Westport
Entity Address, State or Province	CT
Entity Address, Postal Zip Code	06880
City Area Code	(203)
Local Phone Number	409-5444
Title of 12(b) Security	Common Stock, par value $0.001 per share
Security Exchange Name	NASDAQ
Entity Interactive Data Current	Yes
Auditor Firm ID	711
Auditor Name	Friedman LLP
Auditor Location	Marlton, New Jersey

CONSOLIDATED BALANCE SHEETS

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Current assets:
Cash	$ 11,659	$ 28,268
Inventory	1,881	768
Prepaid expenses and vendor deposits	354	301
Total current assets	13,894	29,337
Property and equipment, net	652	289
Right-to-use assets, net	604	306
Other assets:
Patents, net	326	346
Trademarks	1	1
Prepaid expenses, long term	0	5
Deposits	42	102
Total assets	15,519	30,386
Current liabilities:
Accounts payable and accrued expenses, including $317 and $40 to related parties as of December 31, 2020 and 2019, respectively	2,179	4,722
Deferred revenue, short term	32	0
Dividends payable	82	73
Lease liability, short term	283	313
Total current liabilities	2,576	5,108
Deferred revenue, long term	5	0
Lease liability, long term	373	1
Total long-term liabilities	378	1
Total liabilities	2,954	5,109
Convertible Preferred Stock	105	105
Equity:
Preferred stock	0	0
Common stock, $0.001 par value, authorized 200,000,000 shares, 30,764,792 and 23,323,087 issued and outstanding as of December 31, 2020 and 2019, respectively	36	31
Additional paid in capital	201,127	181,344
Accumulated deficit	(188,922)	(157,005)
Total stockholders' equity (deficit)	12,241	24,370
Non-controlling interest	219	802
Total equity	12,460	25,172
Total liabilities and stockholders' equity (deficit)	$ 15,519	$ 30,386

CONSOLIDATED BALANCE SHEETS (Pa

CONSOLIDATED BALANCE SHEETS (Parentheticals) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Accounts payable and accrued expenses, related parties (in Dollars)	$ 86	$ 317
Preferred Stock, shares issued	105	105
Preferred Stock, shares outstanding	105	105
Preferred Stock, liquidation preference (in Dollars)	$ 105	$ 105
Preferred stock, par value (in Dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized	1,000,000	1,000,000
Common stock, par value (in Dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized	200,000,000	200,000,000
Common stock, shares issued	35,567,180	30,764,792
Common stock, shares outstanding	35,567,180	30,764,792
Series A Preferred Stock [Member]
Preferred stock, shares authorized	200	200
Series B Preferred Stock [Member]
Preferred stock, shares authorized	600	600
Series C Preferred Stock [Member]
Preferred Stock, shares issued		105
Preferred Stock, shares outstanding		105
Preferred stock, shares authorized	4,200	4,200
Series D Preferred Stock [Member]
Preferred stock, shares authorized	1,400	1,400
Series E Preferred Stock [Member]
Preferred stock, shares authorized	1,000	1,000
Series F Preferred Stock [Member]
Preferred stock, shares authorized	200,000	200,000

CONSOLIDATED STATEMENTS OF OPER

CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Revenue	$ 441	$ 0
Cost of goods sold	199	0
Gross profit	242	0
Research and development	5,602	18,136
General and administrative	27,853	40,954
Depreciation and amortization	198	94
Total operating expenses	33,653	59,184
Loss from operations	(33,411)	(59,184)
Other income (expense):
Interest income, net	2	45
Gain on settlement of debt	553	0
Loss on foreign currency translation	0	(1)
Loss before income taxes	(32,856)	(59,140)
Income taxes (benefit)	0	0
Net loss	(32,856)	(59,140)
Non-controlling interest	939	6,922
Net loss attributable to BioSig Technologies, Inc.	(31,917)	(52,218)
Preferred stock dividend	(9)	(14)
NET LOSS ATTRIBUTABLE TO COMMON SHAREHOLDERS	$ (31,926)	$ (52,232)
Net loss per common share, basic and diluted (in Dollars per share)	$ (0.95)	$ (1.87)
Weighted average number of common shares outstanding, basic and diluted (in Shares)	33,511,941	27,906,584
Product [Member]
Revenue	$ 414	$ 0
Service [Member]
Revenue	$ 27	$ 0

CONSOLIDATED STATEMENT OF STOCK

CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY (DEFICIT) - USD ($) $ in Thousands	Series D Preferred Stock [Member]Common Stock [Member]At-the-Market Offering [Member]	Series D Preferred Stock [Member]Common Stock [Member]Settlement of Preferred Stock [Member]	Series D Preferred Stock [Member]Common Stock [Member]Cashless Exercise of Warrants [Member]	Series D Preferred Stock [Member]Common Stock [Member]Exercise of Options [Member]	Series D Preferred Stock [Member]Common Stock [Member]Exercise of Warrants [Member]	Series D Preferred Stock [Member]Common Stock [Member]	Series E Preferred Stock [Member]Additional Paid-in Capital [Member]At-the-Market Offering [Member]	Series E Preferred Stock [Member]Additional Paid-in Capital [Member]Settlement of Preferred Stock [Member]	Series E Preferred Stock [Member]Additional Paid-in Capital [Member]Exercise of Options [Member]	Series E Preferred Stock [Member]Additional Paid-in Capital [Member]Exercise of Warrants [Member]	Series E Preferred Stock [Member]Additional Paid-in Capital [Member]Trek Therapeutics, PBC [Member]	Series E Preferred Stock [Member]Additional Paid-in Capital [Member]	Series E Preferred Stock [Member]Retained Earnings [Member]	Series C Preferred Stock [Member]Settlement of Preferred Stock [Member]	Series C Preferred Stock [Member]	Noncontrolling Interest [Member]Trek Therapeutics, PBC [Member]	Noncontrolling Interest [Member]	At-the-Market Offering [Member]	Exercise of Options [Member]	Exercise of Warrants [Member]	Trek Therapeutics, PBC [Member]	Total
Balance at Dec. 31, 2019						$ 23						$ 115,910	$ (104,787)				$ 515					$ 11,661
Balance (in Shares) at Dec. 31, 2019						23,323,087
Sale of common stock						$ 5	$ 2,228					25,210						$ 2,228				25,215
Sale of common stock (in Shares)	424,357					4,687,500
Sale of subsidiary shares to non-controlling interest												7,124					3,468					$ 10,592
Sale of subsidiary shares to non-controlling interest (in Shares)																						83,055
Common stock issued for services						$ 1						4,399										$ 4,400
Common stock issued for services (in Shares)						679,555
Fair value of subsidiary shares issued to acquire research and development											$ 2,439	1,051				$ 735	248				$ 3,174	1,299
Stock based compensation												17,983					2,782					20,765
Stock based compensation (in Shares)						219,334
Preferred Stock dividend												(14)										(14)
Net loss													(52,218)				(6,922)					$ (59,140)
Common stock issued upon conversion of preferred stock and accrued dividends								$ 70				110		$ 70	$ 110
Common stock issued upon conversion of preferred stock and accrued dividends (in Shares)		15,516				29,334
Common stock issued upon exercise of warrants					$ 1					$ 2,089										$ 2,090
Common stock issued upon exercise of warrants (in Shares)			12,840		542,646
Common stock issued in exchange for subsidiary shares												24					(24)
Common stock issued in exchange for subsidiary shares (in Shares)						83,055									44,850
Common stock issued upon exercise of options				$ 1					$ 2,721										$ 2,722
Common stock issued upon exercise of options (in Shares)				586,825		160,743																1,203,223
Balance at Dec. 31, 2020						$ 31						181,344	(157,005)				802					$ 25,172
Balance (in Shares) at Dec. 31, 2020						30,764,792																30,764,792
Sale of common stock							$ 1,300											$ 1,300
Sale of common stock (in Shares)	251,720
Change in fair value of modified options												313					8					$ 321
Sale of subsidiary shares to non-controlling interest						$ 3						9,001										9,004
Sale of subsidiary shares to non-controlling interest (in Shares)						2,500,000
Common stock issued for services						$ 1						3,974										3,975
Common stock issued for services (in Shares)						1,124,341
Stock based compensation						$ 1						5,176					348					5,525
Stock based compensation (in Shares)						916,952
Preferred Stock dividend												(9)										(9)
Net loss													(31,917)				(939)					$ (32,856)
Common stock issued upon conversion of preferred stock and accrued dividends								$ 28						$ 28
Common stock issued upon conversion of preferred stock and accrued dividends (in Shares)		9,375
Common stock issued upon exercise of options (in Shares)																			9,375			9,375
Balance at Dec. 31, 2021						$ 36						$ 201,127	$ (188,922)				$ 219					$ 12,460
Balance (in Shares) at Dec. 31, 2021						35,567,180																35,567,180

CONSOLIDATED STATEMENT OF STO_2

CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY (DEFICIT) (Parentheticals)	12 Months Ended
	Dec. 31, 2021USD ($)$ / shares	Dec. 31, 2020USD ($)$ / shares
Sale of common stock, transactional costs (in Dollars) | $	$ 995,000
Options, per share	$ 2.96	$ 5.08
Warrants, per share		$ 3.75
At-the-Market Offering [Member]
Sale of common stock, transactional costs (in Dollars) | $	$ 40,000	$ 222,000
Series D Preferred Stock [Member] | Common Stock [Member]
Preferred Stock, per share		$ 3.75
Series D Preferred Stock [Member] | Common Stock [Member] | Settlement of Preferred Stock [Member]
Preferred Stock, per share		4.53
Options, per share	$ 2.96
Series D Preferred Stock [Member] | Common Stock [Member] | Exercise of Options [Member]
Options, per share		4.64
Series D Preferred Stock [Member] | Common Stock [Member] | Exercise of Warrants [Member]
Warrants, per share		$ 3.88

CONSOLIDATED STATEMENTS OF CASH

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (32,856,000)	$ (59,140,000)
Adjustments to reconcile net loss to cash used in operating activities:
Depreciation	198,000	94,000
Non-cash lease expense	441,000	456,000
Equity based compensation	9,500,000	25,165,000
Gain on settlement of debt	(553,000)	0
Change in fair value of modified options	321,000	0
Fair value of subsidiary stock issued to acquire research and development from Trek Therapeutics, PBC	0	3,174,000
Fair value of subsidiary stock issued to acquire research and development	0	1,299,000
Changes in operating assets and liabilities:
Inventory	(1,114,000)	(287,000)
Prepaid expenses	(50,000)	(119,000)
Deferred revenue	38,000	0
Payment of long term deposit	60,000	(18,000)
Accounts payable	(1,988,000)	3,233,000
Operating lease liabilities	(396,000)	(458,000)
Net cash used in operating activities	(26,399,000)	(26,601,000)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of property and equipment	(542,000)	(87,000)
Net cash used in investing activity	(542,000)	(87,000)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from sale of common stock	9,004,000	25,215,000
Proceeds from sale subsidiary stock to non-controlling interest, net of issuance costs	0	10,592,000
Proceeds from sale of common stock under a At-the-market offering, net of issuance costs	1,300,000	2,228,000
Proceeds from exercise of options	28,000	2,722,000
Proceeds from exercise of warrants	0	2,090,000
Net cash provided by financing activities	10,332,000	42,847,000
Net increase in cash and cash equivalents	(16,609,000)	16,159,000
Cash and cash equivalents, beginning of the period	28,268,000	12,109,000
Cash and cash equivalents, end of the period	11,659,000	28,268,000
Supplemental disclosures of cash flow information:
Cash paid during the period for interest	0	0
Cash paid during the period for income taxes	0	0
Noncash investing and financing activities:
Dividend payable on preferred stock charged to additional paid in capital	9,000	14,000
Record right-to-use assets and related lease liability	800,000	2,000
Series C Preferred Stock [Member]
Noncash investing and financing activities:
Common stock issued upon conversion preferred stock and accrued dividends	$ 0	$ 180,000

NATURE OF OPERATIONS AND BASIS

NATURE OF OPERATIONS AND BASIS OF PRESENTATION	12 Months Ended
	Dec. 31, 2021
Accounting Policies [Abstract]
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]	NOTE 1 NATURE OF OPERATIONS AND BASIS OF PRESENTATION Business and organization BioSig Technologies, Inc. was initially incorporated on February 24, 2009 under the laws of the State of Nevada and subsequently re-incorporated in the state of Delaware in 2011. The Company is principally devoted to improving the standard care in electrophysiology with our PURE EP System’s enhanced signal acquisition, digital signal processing, and analysis during ablation of cardiac arrhythmias. The Company has generated minimal revenue to date and consequently its operations are subject to all risks inherent in business enterprises in early commercialization stage. On November 7, 2018, the Company formed a subsidiary under the laws of the State of Delaware originally under the name of NeuroClear Technologies, Inc. which was renamed to ViralClear Pharmaceuticals, Inc. (“ViralClear”) in March 2020. The subsidiary was established to pursue additional applications of the PURE EP™ signal processing technology outside of cardiac electrophysiology, and subsequently in 2020, was repurposed to develop merimepodib, a broad-spectrum anti-viral agent that showed potential for the treatment of COVID-19. Since late 2020, ViralClear has been realigned with its original objective of pursuing additional applications of the PURE EP™ signal processing technology outside of cardiac electrophysiology. In 2019 and 2020, ViralClear sold an aggregate of 1,965,240 shares of its common stock to investors for net proceeds of $15.6 million and issued an aggregate of 894,869 shares of its common stock in connection with acquiring assets and with know-how agreements. As of December 31, 2021, the Company had a majority interest in ViralClear of 68.44%. On July 2, 2020, the Company formed an additional subsidiary, NeuroClear Technologies, Inc., a Delaware corporation. COVID-19 On March 11, 2020, the World Health Organization declared a pandemic related to the rapidly spreading coronavirus (COVID-19) outbreak, which has led to a global health emergency. The full public-health impact of the ongoing pandemic is currently indeterminable and rapidly evolving, and the related health crisis has adversely affected and may continue to adversely affect the global economy, resulting in delaying to our commercialization objectives of the PURE EP Systems into 2022.

GOING CONCERN AND MANAGEMENT'S

GOING CONCERN AND MANAGEMENT'S LIQUIDITY PLANS	12 Months Ended
	Dec. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Substantial Doubt about Going Concern [Text Block]	NOTE 2 GOING CONCERN AND MANAGEMENT S LIQUIDITY PLANS As of December 31, 2021, the Company had cash of $11.7 million and working capital of $11.3 million. The Company raised $10.3 million through the sale of common stock. Subsequent to December 31, 2021, the Company raised approximately $3 million from the sale of common stock and warrants. During the year ended December 31, 2021, the Company used net cash in operating activities of $26.4 million. These conditions raise substantial doubt about the Company’s ability to continue as a going concern. The Company’s primary source of operating funds since inception has been cash proceeds from sale of of common and preferred stock. The Company has experienced net losses and negative cash flows from operations since inception and expects these conditions to continue for the foreseeable future. The Company’s plans include the continued commercialization of the PURE EP System and other applications of our core technology and raising capital through the sale of additional equity securities, debt or capital inflows from strategic partnerships. The Company’s strategic shift from a focus on technology development to commercialization will allow the Company to significantly reduce operating expenses. The Company will require additional financing to fund future operations. Further, although the Company began commercial operations; there is no assurance that the Company will be able to generate sufficient cash flow to fund operations. In addition, there can be no assurance that the Company’s continuing research and development will be successfully completed or that any additional products will be commercially viable. Accordingly, the accompanying consolidated financial statements have been prepared in conformity with U.S. GAAP, which contemplates continuation of the Company as a going concern and the realization of assets and satisfaction of liabilities in the normal course of business. The carrying amounts of assets and liabilities presented in the consolidated financial statements do not necessarily purport to represent realizable or settlement values. The consolidated financial statements do not include any adjustment that might result from the outcome of this uncertainty.

SUMMARY OF SIGNIFICANT ACCOUNTI

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	12 Months Ended
	Dec. 31, 2021
Accounting Policies [Abstract]
Significant Accounting Policies [Text Block]	NOTE 3 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES A summary of the significant accounting policies applied in the preparation of the accompanying consolidated financial statements follows. Principals of consolidation The accompanying consolidated financial statements include the accounts of BioSig Technologies, Inc. and its majority owned subsidiary, ViralClear Pharmaceuticals, Inc., and wholly owned subsidiary, NeuroClear Technologies, Inc. herein referred to as the “Company” or “BioSig”. All significant intercompany accounts and transactions have been eliminated in consolidation. Use of Estimates The preparation of these consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Significant estimates include the recoverability and useful lives of long-lived assets, fair value of acquired assets, stock-based compensation and the valuation allowance related to deferred tax assets. Actual results may differ from these estimates. Revenue Recognition The Company derives its revenue primarily from the sale of its medical device, the PURE EP™ System, and well as related support and maintenance services and software upgrades in connection with the system. The Company recognizes revenue in accordance with Accounting Standards Codification (ASC) 606, Revenue from Contracts with Customers the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The Company determines revenue recognition through the following five steps: ● Identify the contract with the customer; ● Identify the performance obligations in the contract; ● Determine the transaction price; ● Allocate the transaction price to the performance obligation in the contract; and ● Recognize revenue when, or as, the performance obligations are satisfied. Performance obligations are the unit of accounting for revenue recognition and generally represent the distinct goods or services that are promised to the customer. If the Company determines that it has not satisfied a performance obligation, it will defer recognition of the revenue until the performance obligation is deemed to be satisfied. Once the PURE EP system is delivered, installed, and accepted by the customer, our performance obligation is recognized. Support, maintenance, and software upgrades are performance obligations over a defined period and are recognized ratably over the contractual service period. Customers typically purchase these services with the initial sale of the PURE EP System and do not have the right to terminate their contracts unless we fail to perform material obligations. The Company may execute more than one contract with a single customer. If so, it is evaluated whether the agreements were negotiated as a package with a single objective, whether the amount of consideration to be paid in one agreement depends on the price and/or performance of another agreement, or whether the goods or services promised in the agreements represent a single performance obligation. The conclusions reached can impact the allocation of the transaction price to each performance obligation and the timing of revenue recognition related to those arrangements. The Company records accounts receivable for amounts invoiced to customers for which the Company has an unconditional right to consideration as provided under the contractual arrangement. Unbilled receivables, if any, include amounts related to the Company’s contractual right to consideration for completed performance obligations not yet invoiced. Deferred revenue includes payments received in advance of performance under the contract. Our unbilled receivables and deferred revenue are reported on an individual contract basis at the end of each reporting period. Unbilled receivables are classified as current or noncurrent based on the timing of when we expect to bill the customer. Deferred revenue is classified as current or noncurrent based on the timing of when we expect to recognize revenue. The Company’s unconditional right to consideration for goods and services transferred to the customer is included in accounts receivable, net (if any) in the Company’s consolidated balance sheet. There are no contract liabilities for the year ended December 31, 2020. A reconciliation of contract liabilities with customers for the year ended December 31, 2021, are presented below: Balance at December 31, 2020 (000’s) Consideration Received (000’s) Recognized in Revenue (000’s) Balance at December 31, 2021 (000’s) Product revenue $ - $ 414 $ (414 ) $ - Service revenue - 64 (27 ) 37 Total $ - $ 478 $ (441 ) $ 37 The table below summarizes our deferred revenue as of December 31, 2021 and 2020: December 31, 2021 (000’s) December 31, 2020 (000’s) Deferred revenue-current $ 32 $ - Deferred revenue-noncurrent 5 - Total deferred revenue $ 37 $ - The Company had two customers which accounted for approximately 68% and 32% of their revenue in the year ended December 31, 2021. The Company utilized one contract manufacturer for the manufacture and supply of the Pure EP system for the years ended December 31, 2021 and 2020. Cost of Goods Sold Cost of goods sold consists primarily of the delivered cost of our medical device(s) sold. Allowance for Doubtful Accounts The Company adjusts accounts receivable down to net realizable value with its allowance methodology. In determining the allowance for doubtful accounts for estimated losses, aged receivables are analyzed periodically by management. Each identified receivable is reviewed based upon historical collection experience, financial condition of the client and the status of any open or unresolved issues with the client preventing the payment thereof. Corrective action, if necessary, is taken by the Company to resolve open issues related to unpaid receivables. The allowance for doubtful accounts was $0 at December 31, 2021 and 2020. The Company believes that its reserve is adequate, however results may differ in future periods. For the year ended December 31, 2021 and 2020, bad debt expense totaled $0. Fair Value of Financial Instruments Accounting Standards Codification subtopic 825-10, Financial Instruments (“ASC 825-10”) requires disclosure of the fair value of certain financial instruments. The carrying value of cash, accounts payable and accrued liabilities as reflected in the balance sheets, approximate fair value because of the short-term maturity of these instruments. All other significant financial assets, financial liabilities and equity instruments of the Company are either recognized or disclosed in the financial statements together with other information relevant for making a reasonable assessment of future cash flows, interest rate risk and credit risk. Where practicable the fair values of financial assets and financial liabilities have been determined and disclosed; otherwise only available information pertinent to fair value has been disclosed. The Company follows Accounting Standards Codification subtopic 820-10, Fair Value Measurements and Disclosures (“ASC 820-10”) and ASC 825-10, which permits entities to choose to measure many financial instruments and certain other items at fair value. Concentrations of Credit Risk Financial instruments and related items, which potentially subject the Company to concentrations of credit risk, consist primarily of cash and cash equivalents. The Company places its cash and temporary cash investments with credit quality institutions. At times, such amounts may be in excess of the FDIC insurance limit. At December 31, 2021 and 2020, deposits in excess of FDIC limits were $11.2 million and $27.8 million, respectively. Inventory The inventory is comprised of work in process and finished goods available for sale and are stated at the lower of cost or net realizable value using specific identification method for serial numbered inventory and first-in, first-out method for all other inventory for valuation. The inventory at December 31, 2021 and 2020 were $1.9 million and $0.8 million, respectively, comprised of finished goods. Prepaid Expenses and Vendor Deposits Prepaid expenses and vendor deposits are comprised of prepaid insurance, operating expenses and other prepayments. Leases The Company determines if a contractual arrangement is a lease at inception. Operating leases are included in operating lease right-of-use (“ROU”) assets, current operating lease liabilities, and noncurrent operating lease liabilities on the Company’s consolidated balance sheet. The Company evaluates and classifies leases as operating or finance leases for financial reporting purposes. The classification evaluation begins at the commencement date and the lease term used in the evaluation includes the non-cancellable period for which the Company has the right to use the underlying asset, together with renewal option periods when the exercise of the renewal option is reasonably certain and failure to exercise such option which result in an economic penalty. All the Company’s real estate leases are classified as operating leases. ROU assets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent the Company’s obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at the commencement date of the lease based on the present value of lease payments over the lease term. The lease payments included in the present value are fixed lease payments. As most of the Company’s leases do not provide an implicit rate, the Company estimates its collateralized incremental borrowing rate, based on information available at the commencement date, in determining the present value of lease payments. The Company applies the portfolio approach in applying discount rates to its classes of leases. The operating lease ROU assets include any payments made before the commencement date. Lease expense for lease payments is recognized on a straight-line basis over the lease term. The Company does not currently have subleases. The Company does not currently have residual value guarantees or restrictive covenants in its leases. Property and Equipment Property and equipment are stated at cost and depreciated using the straight-line method over their estimated useful lives of 3 to 5 years. When retired or otherwise disposed, the related carrying value and accumulated depreciation are removed from the respective accounts and the net difference less any amount realized from disposition, is reflected in earnings. Impairment of Long-lived Assets The Company recognizes an impairment of long-lived assets used in operations, other than goodwill, when events or circumstances indicate that the asset might be impaired and the estimated undiscounted cash flows to be generated by those assets over their remaining lives are less than the carrying amount of those items. The net carrying value of assets not recoverable is reduced to fair value, which is typically calculated using the discounted cash flow method. The Company did not recognize and record any impairments of long-lived assets used in operations during the years ended December 31, 2021 and 2020. Research and Development Costs The Company accounts for research and development costs in accordance with the Accounting Standards Codification subtopic 730-10, Research and Development (“ASC 730-10”). Under ASC 730-10, all research and development costs must be charged to expense as incurred. Accordingly, internal research and development costs are expensed as incurred. Third-party research and developments costs are expensed when the contracted work has been performed or as milestone results have been achieved. Company-sponsored research and development costs related to both present and future products are expensed in the period incurred. The Company incurred research and development expenses of $5.6 million and $18.1 million for the year ended December 31, 2021 and 2020, respectively. Acquisition of Intellectual Property Intellectual property acquired are accounted for under the acquisition method of accounting. This method requires the recording of acquired assets, including separately identifiable intangible assets, and assumed liabilities at their acquisition date fair values. Any excess consideration transferred over fair value is allocated on a relative fair value basis to the identifiable net assets. The acquired intellectual property from the Trek acquisition was considered unproven compounds, the success of which was uncertain at the time of the acquisition. Accordingly, the fair value of the consideration paid was charged as acquired research and development to current period operations. Net Income (loss) Per Common Share The Company computes earnings (loss) per share under Accounting Standards Codification subtopic 260-10, Earnings Per Share (“ASC 260-10”). Net loss per common share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the period. Diluted earnings per share, if presented, would include the dilution that would occur upon the exercise or conversion of all potentially dilutive securities into common stock using the “treasury stock” and/or “if converted” methods as applicable. The computation of basic and diluted loss per share as of December 31, 2021 and 2020 excludes potentially dilutive securities when their inclusion would be anti-dilutive, or if their exercise prices were greater than the average market price of the common stock during the period. Potentially dilutive securities excluded from the computation of basic and diluted net income (loss) per share are as follows: December 31, 2021 December 31, 2020 Series C convertible preferred stock 83,468 47,578 Options to purchase common stock 4,568,484 3,568,497 Warrants to purchase common stock 818,910 1,446,200 Restricted stock units to acquire common stock 141,250 218,334 Totals 5,612,112 5,280,609 Stock Based Compensation The Company measures the cost of services received in exchange for an award of equity instruments based on the fair value of the award as measured on the grant date. The fair value amount is then recognized over the period during which services are required to be provided in exchange for the award, usually the vesting period. Income Taxes The Company follows Accounting Standards Codification subtopic 740-10, Income Taxes (“ASC 740-10”) for recording the provision for income taxes. Deferred tax assets and liabilities are computed based upon the difference between the financial statement and income tax basis of assets and liabilities using the enacted marginal tax rate applicable when the related asset or liability is expected to be realized or settled. Deferred income tax expenses or benefits are based on the changes in the asset or liability during each period. If available evidence suggests that it is more likely than not that some portion or all of the deferred tax assets will not be realized, a valuation allowance is required to reduce the deferred tax assets to the amount that is more likely than not to be realized. Future changes in such valuation allowance are included in the provision for deferred income taxes in the period of change. Deferred income taxes may arise from temporary differences resulting from income and expense items reported for financial accounting and tax purposes in different periods. Patents, Net The Company capitalizes certain initial asset costs in connection with patent applications including registration, documentation and other professional fees associated with the application. Patent costs incurred prior to the Company’s U.S. Food and Drug Administration (“FDA”) 510(k) application on March 28, 2018 were charged to research and development expense as incurred. Commencing upon first in-man trials on February 18 and 19, 2019, capitalized costs are amortized to expense using the straight-line method over the lesser of the legal patent term or the estimated life of the product of 20 years. During the year ended December 31, 2021 and 2020, the Company recorded amortization of $19,006 and $19,005 to current period operations, respectively. Warranty The Company generally warrants its products to be free from material defects and to conform to material specifications for a period of up to two (2) years. Warranty expense is estimated based primarily on historical experience and is reflected in the consolidated financial statements. Non-controlling Interest The Company’s non-controlling interest represents the non-controlling shareholders ownership interests related to the Company’s subsidiary, ViralClear. The Company reports its non-controlling interest in subsidiaries as a separate component of equity in the consolidated balance sheets and reports both net loss attributable to the non-controlling interest and net loss attributable to the Company’s common shareholders on the face of the consolidated statements of operations. The Company’s equity interest in ViralClear is 68.44% and the non-controlling stockholders’ interest is 31.56% as of December 31, 2021. This is reflected in the consolidated statements of changes in equity. Segment Information Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision maker, or decision-making group, in making decisions how to allocate resources and assess performance. The information disclosed herein represents all of the material financial information related to the Company’s principal operating segments. (See Note 12 – Segment Reporting). Recent Accounting Pronouncements In June 2016, the FASB issued ASU 2016-13, Financial Instruments-Credit Losses : Measurement of Credit Losses on Financial Instruments In February 2020, the FASB issued ASU 2020-02, Financial Instruments-Credit Losses and Leases Amendments to SEC Paragraphs Pursuant to SEC Staff Accounting Bulletin No. 119 and Update to SEC Section on Effective Date Related to Accounting Standards Update No. 2016-02, Leases There were other various updates recently issued, most of which represented technical corrections to the accounting literature or application to specific industries and are not expected to a have a material impact on the Company’s financial position, results of operations or cash flows.

PROPERTY AND EQUIPMENT

PROPERTY AND EQUIPMENT	12 Months Ended
	Dec. 31, 2021
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment Disclosure [Text Block]	NOTE 4 PROPERTY AND EQUIPMENT Property and equipment as of December 31, 2021 and 2020 is summarized as follows: December 31, 2021 (000’s) December 31, 2020 (000’s) Computer equipment $ 383 $ 234 Furniture and fixtures 88 75 Manufacturing equipment 286 34 Testing/Demo equipment 145 96 Leasehold improvements 79 - Total 981 439 Less accumulated depreciation (329 ) (150 ) Property and equipment, net $ 652 $ 289 Property and equipment are stated at cost and depreciated using the straight-line method over their estimated useful lives of 3 to 5 years. Leasehold improvements are depreciated over the related expected lease term. When retired or otherwise disposed, the related carrying value and accumulated depreciation are removed from the respective accounts and the net difference less any amount realized from disposition, is reflected in earnings. Depreciation expense was $179,136 and $74,527 for years ended December 31, 2021 and 2020, respectively.

RIGHT TO USE ASSETS AND LEASE L

RIGHT TO USE ASSETS AND LEASE LIABILITY	12 Months Ended
	Dec. 31, 2021
Disclosure Text Block [Abstract]
Lessee, Operating Leases [Text Block]	NOTE 5 RIGHT TO USE ASSETS AND LEASE LIABILITY Operating leases: On February 10, 2021 the Company entered into a Sixth Amendment to the Office Lease at 12424 Wilshire Blvd in Los Angeles dated August 9, 2011 – it is the Fourth Extended Term with respect to Suite 745 and the Expansion Term with respect to Suite 740 which is from July 1, 2021 until June 30, 2022 with a fixed monthly rent equal to $13,702 (down from $16,289); and the security deposit will be reduced by $5,448 so that the balance remaining shall be $27,404. The Company determined that the Sixth Amendment was a lease modification and accordingly reassessed the lease classification, remeasured the lease liability and adjusted the right-to-use asset. At February 10, 2021 the Company removed the remaining right-to-use net assets of $60,881 and related lease liability of $63,076 and recorded right-to-use assets and related lease liability of $217,903. On August 2, 2021, the Company exercised its option to extend its Rochester, Minnesota lease of approximately 1,400 square feet of office space for two additional years expiring on October 31, 2023 with a fixed monthly rate of $3,513, increasing to $3,618 for the second year. The Company determined that the lease option exercised was a lease modification and accordingly reassessed the lease classification, remeasured the lease liability and adjusted the right-to-use asset. On August 2, 2021 the Company removed the remaining right-to-use net assets of $10,247 and related lease liability of $10,400 and recorded right-to-use assets and related lease liability of $89,629. At the lease modification date, the Company estimated the lease liability and the right of use assets at present value using the Company’s estimated incremental borrowing rate of 6.5%. On August 3, 2021, the Company entered into a sublease agreement whereby the Company leased approximately 6,590 square feet of office space at 55 Greens Farms Road, Westport, Connecticut commencing September 1, 2021 and expiring December 31, 2024 (40 months) at the initial rate beginning January 1, 2022 of $14,828 with escalating payments. In connection with the lease, the Company paid a security deposit of $14,232. There is no option to extend the lease past its initial term. At the lease commencement date, the Company estimated the lease liability and right-to-use assets at present value using the Company’s incremental borrowing rate of 6.5% and determined their initial present values, at inception, of $492,876. In conjunction with the lease, the Company terminated, without penalty, the sublease at 54 Wilton Road, Westport, CT effective September 4, 2021 and removed the remaining right-to-use assets of $36,756 and related lease liability of $37,625 with a credit to rent expense of $868 relating to the lease termination. As of December 31, 2021, the Company had outstanding five leases with aggregate payments of $32,143 per month, expiring through December 31, 2024. Right to use assets is summarized below: December 31, 2021 (000’s) December 31, 2020 (000’s) Right to use assets, net $ 803 $ 1,087 Less accumulated amortization (199 ) (781 ) Right to use assets, net $ 604 $ 306 During the years ended December 31, 2021 and 2020, the Company recorded $479,746 and $492,844 as lease expense to current period operations, respectively. Lease liability is summarized below: December 31, 2021 (000’s) December 31, 2020 (000’s) Total lease liability $ 656 $ 314 Less: short term portion (283 ) (313 ) Long term portion $ 373 $ 1 Maturity analysis under these lease agreements are as follows (000’s): Year ended December 31, 2022 $ 304 Year ended December 31, 2023 221 Year ended December 31, 2024 191 Total 716 Less: Present value discount (60 ) Lease liability $ 656 Lease expense for the year ended December 31, 2021 and 2020 was comprised of the following: December 31, 2021 (000’s) December 31, 2020 (000’s) Operating lease expense $ 441 $ 456 Short-term lease expense 39 35 Variable lease expense - 2 Total $ 480 $ 493

ACCOUNTS PAYABLE AND ACCRUED EX

ACCOUNTS PAYABLE AND ACCRUED EXPENSES	12 Months Ended
	Dec. 31, 2021
Payables and Accruals [Abstract]
Accounts Payable and Accrued Liabilities Disclosure [Text Block]	NOTE 6 ACCOUNTS PAYABLE AND ACCRUED EXPENSES Accounts payable and accrued expenses at December 31, 2021 and 2020 consist of the following: December 31, 2021 (000’s) December 31, 2020 (000’s) Accrued accounting and legal $ 204 $ 177 Accrued reimbursements and travel 56 56 Accrued consulting 264 256 Accrued research and development expenses 367 3,127 Accrued product purchases 1 30 Accrued marketing 38 - Accrued office and other 84 127 Accrued payroll 552 936 Accrued settlement related to arbitration 613 13 $ 2,179 $ 4,722

SERIES C 9% CONVERTIBLE PREFERR

SERIES C 9% CONVERTIBLE PREFERRED STOCK	12 Months Ended
	Dec. 31, 2021
Disclosure Text Block Supplement [Abstract]
Preferred Stock [Text Block]	NOTE 7 SERIES C 9% CONVERTIBLE PREFERRED STOCK Series C 9% Convertible Preferred Stock On January 9, 2013, the Board of Directors authorized the issuance of up to 4,200 shares of 9% Series C Convertible Preferred Stock (the “Series C Preferred Stock”). The Series C Preferred Stock is entitled to preference over holders of junior stock upon liquidation in the amount of $1,000 plus any accrued and unpaid dividends; entitled to dividends as a preference to holders of junior stock at a rate of 9% per annum of the stated value of $1,000 per share, payable quarterly beginning on September 30, 2013 and are cumulative. The holders of the Series C Preferred Stock vote together with the holders of our common stock on an as-converted basis but may not vote the Series C Preferred Stock in excess of the beneficial ownership limitation of the Series C Preferred Stock. The beneficial ownership limitation is 4.99% of our then outstanding shares of common stock following such conversion or exercise, which may be increased to up to 9.99% of our then outstanding shares of common stock following such conversion or exercise upon the request of an individual holder. The beneficial ownership limitation is determined on an individual holder basis, such that the as-converted number of shares of one holder is not included in the shares outstanding when calculating the limitation for a different holder. As a result of an amendment to the conversion price of our Series C Preferred Stock, the conversion price effective as of December 31, 2020 was $3.75 per share, subject to certain reset provisions. On December 12, 2021, the conversion price was reset to $2.27 per share. The effect was de minimis. The Series C Preferred Stock contains triggering events which would, among other things, require redemption (i) in cash, at the greater of (a) 120% of the stated value of $1,000 or (b) the product of (I) the variable weighted average price of our common stock on the trading day immediately preceding the date of the triggering event and (II) the stated value divided by the then conversion price or (ii) in shares of our common stock, equal to a number of shares equal to the amount set forth in (i) above divided by 75%. As of December 31, 2021 and 2020, the aggregate stated value of our Series C Preferred Stock was $105,000. The triggering events include our being subject to a judgment of greater than $100,000 or our initiation of bankruptcy proceedings. If any of the triggering events contained in our Series C Preferred Stock occur, the holders of our Series C Preferred Stock may demand redemption, an obligation the Company may not have the ability to meet at the time of such demand. The Company will be required to pay interest on any amounts remaining unpaid after the required redemption of our Series C Preferred Stock, at a rate equal to the lesser of 18% per annum or the maximum rate permitted by applicable law. Accordingly, the Company has classified the Series C Preferred Stock as a mezzanine obligation in the accompanying consolidated balance sheets. The Company issued an aggregate of 44,850 shares of its common stock in exchange for 110 shares of the Company’s Series C Preferred stock (stated value of $110,000) and $70,341 accrued dividends for the year ended December 31, 2020. Series C Preferred Stock issued and outstanding totaled 105 as of December 31, 2021 and 2020. As of December 31, 2021 and 2020, the Company has accrued $81,667 and $72,517 dividends payable on the Series C Preferred Stock.

STOCKHOLDER EQUITY

STOCKHOLDER EQUITY	12 Months Ended
	Dec. 31, 2021
Stockholders' Equity Note [Abstract]
Stockholders' Equity Note Disclosure [Text Block]	NOTE 8 STOCKHOLDER EQUITY Shareholder rights plan On July 14, 2020, our board of directors adopted a stockholder rights plan (the “Rights Plan”) and declared a dividend of one preferred share purchase right for each outstanding share of BioSig’s common stock to stockholders of record on July 27, 2020, and one right will be issued for each new share of common stock issued thereafter. Each right will initially trade with common stock, and will allow its holder to purchase from BioSig one one-thousandth of a share of Series F Junior Participating Preferred stock, par value $0.001 per share, for an exercise price of $50.00, once the rights become exercisable. In the event that a person or group acquires beneficial ownership of 12% or more of BioSig’s then outstanding common stock, subject to certain exceptions, each right would entitle its holder (other than such person or members of such group) to purchase additional shares of BioSig’s common stock having a market value of two times the exercise price of the right. In addition, at any time after a person or group acquires 12% or more of BioSig’s outstanding common stock (unless such person or group acquires 50% or more), the Board may exchange one share of BioSig’s common stock for each outstanding right (other than rights owned by such person or group, which would have become void). The Rights Plan could make it more difficult for a third party to acquire control of BioSig or a large block of our common stock without the approval of our board of directors. The rights expired on July 13, 2021. Preferred stock The Company is authorized to issue 1,000,000 shares of $0.001 par value preferred stock. As of December 31, 2021 and 2020, the Company has designated 200 shares of Series A preferred stock, 600 shares of Series B preferred stock, 4,200 shares of Series C Preferred Stock, 1,400 shares of Series D Preferred Stock, 1,000 shares of Series E Preferred Stock and 200,000 shares of Series F Preferred Stock. As of December 31, 2021, and 2020, there were no outstanding shares of Series A, Series B, Series D, Series E and Series F preferred stock. Common stock BioSig Technologies, Inc. The Company is authorized to issue 200,000,000 shares of $0.001 par value common stock. As of December 31, 2021 and 2020, the Company had 35,567,180 and 30,764,792 shares issued and outstanding, respectively. During the year ended December 31, 2020, the Company issued an aggregate of 219,334 shares of its common stock for vested restricted stock units as stock-based compensation. On February 25, 2020, the Company entered into securities purchase agreements with investors pursuant to which the Company issued 2,500,000 shares of common stock for aggregate proceeds of $9,052,331, net of $947,669 in expenses. On June 24, 2020, the Company entered into securities purchase agreements with investors pursuant to which the Company issued 2,187,500 shares of common stock for aggregate proceeds of $16,161,980, net of $1,338,020 in expenses. During the year ended December 31, 2020, the Company issued 679,555 shares of common stock for services at a fair value of $4,399,533 ($6.47 per share). During the year ended December 31, 2020, the Company issued 542,646 shares of common stock in exchange for proceeds of $2,088,997 from the exercise of warrants. During the year ended December 31, 2020, the Company issued 586,825 shares of common stock in exchange for proceeds of $2,722,012 from the exercise of options. During the year ended December 31, 2020, the Company issued 12,840 shares of common stock in exchange for the exercise of 37,841 cashless exercises of warrants. During the year ended December 31, 2020, the Company issued 160,743 shares of common stock in exchange for the exercise of 616,398 cashless exercises of options. During the year ended December 31, 2020, the Company issued 83,055 shares of common stock in exchange for 80,958 previously issued ViralClear shares (see below). In January 2021, the Company issued an aggregate of 658,868 shares of its common stock for services at a fair value previously recorded in 2020 of $2,658,224. On July 2, 2021, the Company entered into securities purchase agreements with investors pursuant to which the Company issued 2,500,000 shares of common stock for aggregate proceeds of $9,004,033, net of $995,966 in expenses. During the year ended December 31, 2021, the Company issued 1,124,341 shares of common stock for services at a fair value of $3,975,451. During the year ended December 31, 2021, the Company issued 9,375 shares of common stock in exchange for proceeds of $27,750 from the exercise of options. During the year ended December 31, 2021, the Company issued an aggregate of 258,084 shares of its common stock for vested restricted stock units. At-The-Market Sale Agreement August 28, 2020, the Company entered into an Open Market Sale Agreement (the “Sales Agreement”) with Jefferies LLC to act as the Company’s sales agent and/or principal (“Jefferies” or the “Agent”), with respect to the issuance and sale of up to $45.0 million of the Company’s shares of common stock from time to time in an at-the-market offering. Upon delivery of a placement notice and subject to the terms and conditions of the Sales Agreement, Jefferies may sell the Shares by any method permitted by law deemed to be an “at the market offering” as defined in Rule 415(a)(4) promulgated under the Securities Act of 1933, as amended. The Company may sell the common stock in amounts and at times to be determined by the Company from time to time subject to the terms and conditions of the Sales Agreement, but it has no obligation to sell any of the shares under the Sales Agreement. The Company or Jefferies may suspend or terminate the offering of shares upon notice to the other party and subject to other conditions. Jefferies will act as sales agent on a commercially reasonable efforts basis consistent with its normal trading and sales practices and applicable state and federal law, rules and regulations and the rules of Nasdaq. The Company paid Agent a commission equal to 3.0% of the gross proceeds from the sale of the shares pursuant to the Sales Agreement. The Company has also agreed to provide Jefferies with customary indemnification and contribution rights. The offering of shares pursuant to the Sales Agreement will terminate upon the earlier of (i) the sale of all common stock subject to the Sales Agreement or (ii) termination of the Sales Agreement in accordance with its terms. The common stock was sold and issued pursuant the Company’s shelf registration statement on Form S-3, which was previously declared effective by the Securities and Exchange Commission, and a related prospectus. From August 28, 2020 through December 31, 2020, the Company sold 424,357 shares of its common stock through the Sales Agreement for net proceeds of $2,228,000, after transactional costs of $222,397. From January 15, 2021 through February 16, 2021, the Company sold 251,720 shares of its common stock through the Open Market Sales Agreement for net proceeds of $1,300,135, after transactional costs of $40,365. On March 25, 2021, the Company delivered written notice to Jefferies to terminate the Sales Agreement effective as of April 8, 2021, pursuant to Section 7(b)(i) thereof. The Company was not subject to any termination penalties related to the termination of the Sales Agreement. ViralClear Pharmaceuticals, Inc. On May 20, 2020, ViralClear and the Company entered into a securities purchase agreement, pursuant to which ViralClear agreed to sell in a private placement transaction an aggregate of 1,068,550 shares of ViralClear’s common stock at $10.00 per share, for an aggregate consideration of $10,592,075. This private placement closed on May 20, 2020. The Company was party to certain 2019 purchase agreements between ViralClear and the private placement investors with respect to a provision in each securities purchase agreement which provides that in the event that (i) ViralClear common stock is not listed on a national securities exchange by October 31, 2020, or (ii) a change of control (as defined in each securities purchase agreement) of ViralClear occurs, whichever is earlier, at the option of the holder of ViralClear common stock, each share of ViralClear common stock may be exchanged into 0.9 of a share our common stock if the ViralClear common stock subject to the share exchange was purchased in the August or September 2019 private placements, or 1.1 shares of our common stock if the ViralClear common stock subject to the share exchange was purchased in the private placement closed in October 2019 through December 2019. In November and December 2020, the Company issued an aggregate of 83,055 shares of its common stock in exchange for 80,958 previously issued shares of ViralClear pursuant with 2019 purchase agreements.

OPTIONS, RESTRICTED STOCK UNITS

OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS	12 Months Ended
	Dec. 31, 2021
Disclosure Text Block Supplement [Abstract]
Shareholders' Equity and Share-based Payments [Text Block]	NOTE 9 OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS BioSig Technologies, Inc. 2012 Equity Incentive Plan On October 19, 2012, the Board of Directors of BioSig Technologies, Inc. approved the 2012 Equity Incentive Plan (“the “Plan”) and terminated the Long-Term Incentive Plan (the “2011 Plan”). The Plan provides for the issuance of options, stock appreciation rights, restricted stock and restricted stock units to purchase up to 14,474,450 (as amended) shares of the Company’s common stock to officers, directors, employees and consultants of the Company. Under the terms of the Plan the Company may issue Incentive Stock Options as defined by the Internal Revenue Code to employees of the Company only and nonstatutory options. The Board of Directors of the Company or a committee thereof administers the Plan and determines the exercise price, vesting and expiration period of the grants under the Plan. However, the exercise price of an Incentive Stock Option should not be less than 110% of fair value of the common stock at the date of the grant for a 10% or more stockholder and 100% of fair value for a grantee who is not 10% stockholder. The fair value of the common stock is determined based on the quoted market price or in absence of such quoted market price, by the administrator in good faith. Additionally, the vesting period of the grants under the Plan will be determined by the administrator, in its sole discretion, with an expiration period of not more than ten years. There are 3,048,522 shares remaining available for future issuance of awards under the terms of the Plan as of December 31, 2021. During the years ended December 31, 2021 and 2020, the Company granted an aggregate of 1,818,000 and 1,070,000 (net of 50,000 canceled) options to officers, directors, and key consultants. During the years ended December 31, 2021 and 2020, the Company issued an aggregate of 1,185,872 and 634,517 stock grants to officers, employees and key consultants under the plan. See Note 8. Options Option valuation models require the input of highly subjective assumptions. The fair value of stock-based payment awards was estimated using the Black-Scholes option model with a volatility figure derived from historical stock prices of the Company. The Company accounts for the expected life of options using the based on the contractual life of options for non-employees. For employees, the Company accounts for the expected life of options in accordance with the “simplified” method, which is used for “plain-vanilla” options, as defined in the accounting standards codification. The following table presents information related to stock options at December 31, 2021: Options Outstanding Options Exercisable Weighted Average Exercisable Exercise Number of Remaining Life Number of Price Options In Years Options $ Under 3.00 1,035,375 9.5 560,000 3.00-3.99 587,466 6.5 387,466 4.00-4.99 1,762,916 6.2 1,151,545 5.00-5.99 156,132 7.1 119,464 6.00-6.99 591,542 5.0 478,846 7.00-7.99 191,720 6.9 177,138 Over 8.00 243,333 6.3 197,351 4,568,484 6.9 3,071,810 A summary of the stock option activity and related information for the Plan for the two years ended December 31, 2021 is as follows: Weighted-Average Weighted-Average Remaining Aggregate Shares Exercise Price Contractual Term Intrinsic Value Outstanding at January 1, 2020 3,980,804 $ 5.58 6.3 $ 3,130,791 Grants 1,120,000 $ 4.98 10.0 - Exercised (1,203,223 ) $ 5.08 Forfeited/expired (329,084 ) $ 5.19 Outstanding at December 31, 2020 3,568,497 $ 5.59 7.0 $ 110,961 Grants 1,818,000 $ 3.69 10.0 $ - Exercised (9,375 ) $ 2.96 Forfeited/expired (808,638 ) $ 6.19 Outstanding at December 31, 2021 4,568,484 $ 4.57 6.9 $ - Exercisable at December 31, 2021 3,071,810 $ 4.83 6.0 $ - The aggregate intrinsic value in the preceding tables represents the total pretax intrinsic value, based on options with an exercise price less than the stock price of BioSig Technologies, Inc. of $2.23 as of December 31, 2021, which would have been received by the option holders had those option holders exercised their options as of that date. On January 10, 2020, BioSig Technologies, Inc. granted 60,000 options to purchase the company stock in connection with the services rendered at the exercise price of $6.00 per share for a term of ten years with quarterly vesting beginning March 31, 2020 for three years. On March 24, 2020, BioSig Technologies, Inc. granted 100,000 options to purchase the company stock in connection with the services rendered at the exercise price of $2.96 per share for a term of ten years with 25,000 vesting immediately and 75,000 quarterly vesting beginning June 30, 2020 for two years. On March 31, 2020, BioSig Technologies, Inc. granted 50,000 options to purchase the company stock in connection with the services rendered at the exercise price of $3.73 per share for a term of ten years with vesting quarterly vesting beginning June 30, 2020 for three years. On August 12, 2020, this option was cancelled and a was replaced for a restricted stock award for 50,000 shares. On April 14, 2020, BioSig Technologies, Inc. granted an aggregate of 625,000 options to purchase the company stock to directors and an employee. The options are exercisable at $4.66 per share for ten years and fully vested and exercisable at the date of grant. On April 14, 2020, BioSig Technologies, Inc. granted an aggregate of 90,000 options to purchase shares of its common stock to employees. The options are exercisable at $4.66 per share for ten years and vest quarterly over three years. On May 20, 2020, BioSig Technologies, Inc. granted an aggregate of 65,000 options to purchase the company stock to consultants and an employee. The options are exercisable at $10.49 per share for ten years with 40,000 fully vested and exercisable at the date of grant and 25,000 options vesting quarterly over three years. On August 26, 2020, BioSig Technologies, Inc. granted an aggregate of 25,000 options to purchase the company stock to three employees at the exercise price of $7.57 per share for a term of ten years with one-third vesting on the one year anniversary and two-thirds vesting quarterly thereafter beginning November 26, 2021 for two years. On October 9, 2020, BioSig Technologies, Inc. granted an aggregate of 105,000 options to purchase the company stock to three employees at the exercise price of $5.03 per share for a term of ten years with one-third vesting on the one year anniversary and two-thirds vesting quarterly thereafter beginning January 9, 2022 for two years. On January 12, 2021, BioSig Technologies, Inc. granted 387,500 options to purchase the company stock in connection with the services rendered at the exercise price of $4.23 per share for a term of ten years with one-third vesting on the one-year anniversary and two-thirds vesting quarterly thereafter beginning January 12, 2022 for two years. On February 16, 2021, BioSig Technologies, Inc. granted 102,000 options to purchase the company stock in connection with the services rendered at the exercise price of $4.97 per share for a term of ten years with one-third vesting on the one year anniversary and two-thirds vesting quarterly thereafter beginning February 16, 2022 for two years. On April 9, 2021, BioSig Technologies, Inc. granted 90,000 options to purchase the company stock in connection with the services rendered at the exercise price of $4.38 per share for a term of ten years with one-third vesting on the one-year anniversary and two-thirds vesting quarterly thereafter beginning April 9, 2022 for two years. On April 13, 2021, BioSig Technologies, Inc. granted 25,000 options to purchase the company stock in connection with the services rendered at the exercise price of $4.42 per share for a term of ten years with one-third vesting on the one-year anniversary and two-thirds vesting quarterly thereafter beginning April 13, 2022 for two years. On May 18, 2021, BioSig Technologies, Inc. granted 150,000 options to purchase the company stock in connection with the services rendered at the exercise price of $3.20 per share for a term of ten years with one-third vesting on the one-year anniversary and two-thirds vesting quarterly thereafter beginning May 18, 2022 for two years. On August 3, 2021, BioSig Technologies, Inc. granted an aggregated of 75,000 options to purchase shares of its common stock to three employees. The options are exercisable at $3.61 per share for ten years with one-third vesting on the first anniversary of the date of grant, and the remaining two-thirds vesting in substantially equal quarterly installments over the following two years. On August 31, 2021, BioSig Technologies, Inc. granted an aggregated of 47,500 options to purchase shares of its common stock to three employees. The options are exercisable at $2.98 per share for ten years with immediate vesting. On September 17, 2021, BioSig Technologies, Inc. granted an aggregated of 40,000 options to purchase shares of its common stock to two employees. The options are exercisable at $2.99 per share for ten years with one-third vesting on the first anniversary of the date of grant, and the remaining two-thirds vesting in substantially equal quarterly installments over the following two years. On October 4, 2021, BioSig Technologies, Inc. granted 50,000 options to purchase shares of its common stock to a newly appointed Board member. The options are exercisable at $2.89 per share for ten years with half immediate vesting and half vesting on September 20, 2022. On December 15, 2021, BioSig Technologies, Inc. granted an aggregate of 351,000 options to purchase shares of its common stock to two employees. The options are exercisable at $2.58 per share for ten years with one-third vesting on the first anniversary of the date of grant, and the remaining two-thirds vesting in substantially equal quarterly installments over the following two years. On December 28, 2021, BioSig Technologies, Inc. granted an aggregate of 425,000 options to purchase shares of its common stock with as compensation to the Company’s Board of Directors. The options are exercisable at $2.44 per share with immediate vesting. Also, on December 28, 2021, BioSig Technologies issued 75,000 options to purchase shares of its common stock to a consultant. The options are exercisable at $2.44 per share with 25,000 options vested immediately and 50,000 options vesting on the one-year anniversary. The following assumptions were used in determining the fair value of options during the years ended December 31, 2021 and 2020: 2021 2020 Risk-free interest rate 0.77% - 1.49 % 0.42% to 1.83 % Dividend yield 0 % 0 % Stock price volatility 82.50% to 95.98 % 86.51% to 93.43 % Expected life 5 – 10 years 5-10 years Weighted average grant date fair value $ 2.55 $ 4.03 On June 28, 2021, in connection with the exit of two members of the Company’s board of directors, the Company extended the life of 145,000 previously issued director options from the contractual 90 days from termination of service to the earlier of the initial life or June 28, 2023. The change in estimated fair value of the modified options of $182,514 was charged to current period operations. The following assumptions were used in determining the change in fair value of the modified options at June 28, 2021: Risk-free interest rate 0.05% - 0.25 % Dividend yield 0 % Stock price volatility 88.57 % Expected life 0.25 – 2 years On June 30, 2021, in connection with the resignation of a member of the Company’s board of directors, the Company entered into a one-year consulting contract and extended the life of 221,240 previously issued director options from the contractual 90 days from termination of service to the earlier of the initial life or two years after service contract completion. The change in estimated fair value of the modified options of $111,402 was charged to current period operations. The following assumptions were used in determining the change in fair value of the modified options on June 30, 2021: Risk-free interest rate 0.06% - 0.46 % Dividend yield 0 % Stock price volatility 88.59 % Expected life 0.59 – 3 years The fair value of all options vesting during the year ended December 31, 2021 and 2020 of $3,357,274 and $5,217,761, respectively, was charged to current period operations. Unrecognized compensation expense of $3,655,519 at December 31, 2021 will be expensed in future periods. Warrants The following table summarizes information with respect to outstanding warrants to purchase common stock of BioSig Technologies, Inc. at December 31, 2021: Exercise Number Expiration Price Outstanding Date $ 4.80 250,000 February 2025 to July 2026 $ 6.16 568,910 November 2027 818,910 On February 25, 2020, BioSig Technologies, Inc. issued warrants to purchase 125,000 shares of its common stock at $4.80 per share, expiring on February 21, 2025, for placement agent services in connection with the sale of the company’s common stock. On July 7, 2021, BioSig Technologies, Inc. issued warrants to purchase 125,000 shares of its common stock at $4.80 per share, expiring on July 2, 2026, for placement agent services in connection with the sale of the company’s common stock. A summary of the warrant activity for the two years ended December 31, 2021 is as follows: Weighted-Average Weighted-Average Remaining Aggregate Shares Exercise Price Contractual Term Intrinsic Value Outstanding at January 1, 2020 2,744,718 $ 5.40 2.2 $ 3,410,763 Issued 125,000 $ 4.80 4.2 - Exercised (580,487 ) $ 3.89 Expired (843,031 ) $ 6.29 Outstanding at December 31, 2020 1,446,200 $ 5.44 3.3 $ 1,500 Issued 125,000 $ 4.80 5.0 Expired (752,290 ) $ 5.00 - - Outstanding at December 31, 2021 818,910 $ 5.74 5.3 $ - Vested and expected to vest at December 31, 2021 818,910 $ 5.74 5.3 $ - Exercisable at December 31, 2021 818,910 $ 5.74 5.3 $ - The aggregate intrinsic value in the preceding tables represents the total pretax intrinsic value, based on options with an exercise price less than the company’s stock price of $2.23 of December 31, 2021, which would have been received by the option holders had those option holders exercised their options as of that date. Restricted Stock Units The following table summarizes the restricted stock activity for the two years ended December 31, 2021: Restricted shares issued as of January 1, 2020 262,668 Granted 175,000 Vested and issued (219,334 ) Restricted shares issued as of December 31, 2020 218,334 Granted 301,000 Vested and issued (258,084 ) Forfeited (120,000 ) Vested restricted shares as of December 31, 2021 - Unvested restricted shares as of December 31, 2021 141,250 In 2020, the Company granted an aggregate of 175,000 restricted stock grants for services with vesting from one year to three years from grant date. On January 4, 2021, the Company granted 220,000 restricted stock units for services with 105,000 vesting one-third on the one-year anniversary and two-thirds vesting quarterly thereafter beginning January 4, 2022 for two years and with 115,000 vesting quarterly for one year. On March 8, 2021 the Company granted 31,000 restricted stock units for services vesting on August 31, 2021. On June 1, 2021, in connection with the termination of an employee, the Company accelerated vesting of 30,000 previously granted restricted stock units from a three-year period to fully vested. The change in vesting of the modified restricted stock unit resulted in a $109,725 charge to current period operations. On June 30, 2021, in connection with the resignation of a member of the Company’s board of directors, the Company accelerated vesting of 50,000 previously granted restricted stock units from a three-year period to fully vested. The change in vesting of the modified restricted stock unit resulted in a $232,375 charge to current period operations. On August 14, 2021 the Company granted 50,000 restricted stock units for services vesting quarterly for one year. Stock based compensation expense related to restricted stock grants was $950,281 and $1,151,676 for the year ended December 31, 2021 and 2020, respectively. As of December 31, 2021, the stock-based compensation relating to restricted stock of $286,417 remains unamortized. ViralClear Pharmaceuticals, Inc. 2019 Long-Term Incentive Plan On September 24, 2019, ViralClear’s Board of Directors approved the 2019 Long-Term Incentive Plan (as subsequently amended, the “ViralClear Plan”). The ViralClear Plan was approved by BioSig as ViralClear’s majority stockholder. The ViralClear Plan provides for the issuance of options, stock appreciation rights, restricted stock and restricted stock units to purchase up to 4,000,000 shares of ViralClear’s common stock to officers, directors, employees and consultants of the ViralClear. Under the terms of the ViralClear Plan, ViralClear may issue Incentive Stock Options as defined by the Internal Revenue Code to employees of ViralClear only and nonstatutory options. The Board of Directors of ViralClear or a committee thereof administers the ViralClear Plan and determines the exercise price, vesting and expiration period of the grants under the ViralClear Plan. However, the exercise price of an Incentive Stock Option should not be less than 110% of fair market value of the common stock at the date of the grant for a 10% or more stockholder and 100% of fair market value for a grantee who is not 10% stockholder. The fair market value of the common stock is determined based on the quoted market price or in absence of such quoted market price, by the administrator in good faith. Additionally, the vesting period of the grants under the ViralClear Plan will be determined by the administrator, in its sole discretion, with an expiration period of not more than ten years. There are 2,330,750 shares remaining available for future issuance of awards under the terms of the ViralClear Plan. ViralClear Options A summary of the stock option activity and related information for the ViralClear Plan for the two years ended December 31, 2021 is as follows: Weighted-Average Weighted-Average Remaining Shares Exercise Price Contractual Term Outstanding at January 1, 2020 575,000 $ 5.00 9.3 Grants 1,599,173 $ 5.31 9.6 Forfeited/expired (646,507 ) $ 5.77 Outstanding at December 31, 2020 1,527,666 $ 5.00 4.0 Exercised (550,000 ) $ 5.00 Forfeited/expired (852,666 ) $ 5.00 Outstanding at December 31, 2021 125,000 $ 5.00 7.2 Exercisable at December 31, 2021 83,331 $ 5.00 6.6 The following table presents information related to stock options at December 31, 2021: Options Outstanding Options Exercisable Weighted Average Exercisable Exercise Number of Remaining Life Number of Price Options In Years Options $ 5.00 125,000 7.2 83,331 The fair value of the stock-based payment awards was estimated using the Black-Scholes option model with a volatility figure derived from an index of historical stock prices of comparable entities with the market value of stock price based on recent sales. The Company accounts for the expected life of options in accordance with the “simplified” method, which is used for “plain-vanilla” options, as defined in the accounting standards codification. The risk-free interest rate was determined from the implied yields of U.S. Treasury zero-coupon bonds with a remaining life consistent with the expected term of the options. In 2020, ViralClear granted an aggregate of 1,599,173 options to purchase shares with an exercise price of $5.00 to $10.00 for ten years with 1,278,999 vested immediately, 120,174 quarterly over one year and 200,000 quarterly over two years. The following assumptions were used in determining the change in fair value of the ViralClear options for the year ended December 31, 2020: Risk-free interest rate 0.36% to 0.52 % Dividend yield 0 % Stock price volatility 125.16% to 126.03 % Expected life 5 – 6 years Weighted average grant date fair value $ 4.51 On July 1, 2021, ViralClear issued 206,250 shares of its common stock in exchange for the cashless exercise of 550,000 options previously granted on October 16, 2019. On June 30, 2021, in connection with the resignation of a member of the Company’s board of directors, the Company entered into a one-year consulting contract and extended the life of 25,000 previously issued director options from the contractual 90 days from termination of service to the earlier of the initial life or two years after service contract completion. The change in estimated fair value of the modified options of $26,577 was charged to current period operations. The following assumptions were used in determining the change in fair value of the modified options at June 30, 2021: Risk-free interest rate 0.07% - 0.46 % Dividend yield 0 % Stock price volatility 88.59 % Expected life 1.25 - 3 years The fair value of all options vesting during the years ended December 31, 2021 and 2020 of $146,083 and $5,873,376, respectively, was charged to current period operations. Unrecognized compensation expense of $182,604 at December 31, 2021 will be expensed in future periods. Warrants (ViralClear) The following table presents information related to warrants (ViralClear) at December 31, 2021: Exercise Number Expiration Price Outstanding Date $ 5.00 473,772 November 2027 10.00 6,575 May 2025 480,347 On May 20, 2020, ViralClear issued warrants to purchase 6,575 shares of its common stock at $10.00 per share, expiring on May 20, 2025, for placement agent services in connection with the sale of ViralClear’s common stock. Restricted stock units (ViralClear) The following table summarizes the restricted stock activity for the two years ended December 31, 2021: Restricted shares outstanding at January 1, 2020: 40,000 Granted 1,380,716 Restricted shares outstanding at December 31, 2020: 1,420,716 Issued (40,000 ) Forfeited (62,037 ) Total restricted shares outstanding at December 31, 2021: 1,318,679 Comprised of: Vested restricted shares as of December 31, 2021 678,679 Unvested restricted shares as of December 31, 2021 640,000 Total 1,318,679 On March 25, 2020, ViralClear granted an aggregate of 338,000 restricted stock units to two ViralClear board members for services vesting immediately. On March 30, 2020, ViralClear granted an aggregate of 960,000 restricted stock units to ViralClear board members and employees for services with 320,000 vesting immediately, and 640,000 vesting upon ViralClear meeting certain milestones. On July 13, 2020, ViralClear granted 82,716 restricted stock units to a consultant for services with vesting monthly over one year from date of grant. Stock based compensation expense related to restricted stock unit grants of ViralClear was $904,112 and $5,893,320 for the years ended December 31, 2021 and 2020, respectively. As of December 31, 2021, the stock-based compensation relating to restricted stock of $186,047 remains unamortized.

NON-CONTROLLING INTEREST

NON-CONTROLLING INTEREST	12 Months Ended
	Dec. 31, 2021
Noncontrolling Interest [Abstract]
Noncontrolling Interest Disclosure [Text Block]	NOTE 10 NON-CONTROLLING INTEREST On November 7, 2018, the Company formed a subsidiary, now known as ViralClear, to pursue additional applications of the PURE EP™ signal processing technology outside of cardiac electrophysiology, and subsequently in 2020, was repurposed to develop merimepodib, a broad-spectrum anti-viral agent that showed potential for the treatment of COVID-19. Since late 2020, ViralClear has been realigned with its original objective of pursuing additional applications of the PURE EP™ signal processing technology outside of cardiac electrophysiology. On March 24, 2020, ViralClear entered into an asset purchase agreement (the “Asset Purchase Agreement”) with Trek Therapeutics, PBC (“Trek”), a related party; an entity controlled by a member of the Company’s board of directors. Pursuant to the Asset Purchase Agreement, Trek sold to ViralClear all right, title and interest of Trek and its affiliates to certain assets (the “Purchased Assets”). As consideration for the Purchased Assets, ViralClear agreed to pay Trek in upfront and milestone payments a combination of cash, shares of ViralClear’s common stock, which common stock may equal up to 10% of ViralClear’s outstanding equity, and sublicense fees in the event ViralClear sublicenses the Purchased Assets. On March 30, 2020, pursuant to the Asset Purchase Agreement, ViralClear paid $350,000 in cash and issued 634,910 shares of ViralClear’s common stock valued at $3,174,550 to Trek. In addition, in the event of sublicensing, sale, transfer, assignment or similar transaction, ViralClear agreed to pay Trek 10% of the consideration received. As part of the Purchased Assets, ViralClear received an assignment and licensing rights agreement from Trek with a third-party vendor regarding certain formulas and compounds usage. The agreement, as amended on September 2, 2020, calls for milestone payments upon marketing authorization (as defined) in any first and second country of $10 million and $5 million, respectively, in addition to 6% royalty payments. The common stock issued, and cash paid was accounted for as acquired research and development. On April 8, 2020, ViralClear entered into a know-how license agreement (the “Agreement”) with Mayo Foundation for Medical Education and Research (“Mayo”). In connection with the Agreement, ViralClear issued to Mayo 259,959 shares of ViralClear’s common stock, par value $0.001 per share. On May 20, 2020, ViralClear entered into securities purchase agreements with investors pursuant to which the Company issued 1,068,550 shares of its common stock for aggregate proceeds of $10,592,075, net of $93,425 in expenses. In November and December 2020, the Company issued an aggregate of 83,055 shares of its common stock in exchange for 80,958 previously issued shares of ViralClear pursuant with 2019 purchase agreements. On April 1, 2021, ViralClear issued an aggregate of 40,000 shares of its common stock in exchange for vested restricted stock units. On July 1, 2021, ViralClear issued an aggregate of 206,250 shares of its common stock in exchange for the cashless exercise of 550,000 previously issued options. As of December 31, 2021, the Company had a majority interest in ViralClear of 68.4%. A reconciliation of the ViralClear Pharmaceuticals, Inc. non-controlling loss attributable to the Company: Net loss attributable to the non-controlling interest for the year ended December 31, 2021 (000’s): Net loss $ (3,077 ) Average Non-controlling interest percentage of profit/losses 30.44 % Net loss attributable to the non-controlling interest $ (939 ) Net loss attributable to the non-controlling interest for the year ended December 31, 2020 (000’s): Net loss $ (28,372 ) Average Non-controlling interest percentage of profit/losses 24.40 % Net loss attributable to the non-controlling interest $ (6,922 ) The following table summarizes the changes in non-controlling interest for the two years ended December 31, 2021 (000’s): Balance, January 1, 2020 $ 515 Allocation of equity to non-controlling interest due to equity-based compensation issued 2,782 Allocation of equity to non-controlling interest due to sale of common stock 3,468 Allocation of equity to non-controlling interest due to issuance of equity to acquire Trek and research and development 983 Allocation of equity from non-controlling interest due to parent reacquiring shares shareholders (24 ) Net loss attributable to non-controlling interest (6,922 ) Balance, December 31, 2020 802 Allocation of equity to non-controlling interest due to equity-based compensation issued 348 Allocation of equity to non-controlling interest to due change in fair value of modified option 8 Net loss attributable to non-controlling interest (939 ) Balance, December 31, 2021 $ 219

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	12 Months Ended
	Dec. 31, 2021
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies Disclosure [Text Block]	NOTE 11 COMMITMENTS AND CONTINGENCIES Operating leases See Note 5 for operating lease discussion Licensing agreements 2017 Know-How License Agreement On March 15, 2017, the Company entered into a know-how license agreement with Mayo Foundation for Medical Education and Research whereby the Company was granted an exclusive license, with the right to sublicense, certain know how and patent applications in the field of signal processing, physiologic recording, electrophysiology recording, electrophysiology software and autonomics to develop, make and offer for sale. The agreement expires in ten years from the effective date. The Company is obligated to pay to Mayo Foundation a 1% or 2% royalty payment on net sales of licensed products, as defined. Patent and Know-How License Agreement EP Software Agreement On November 20, 2019, the Company entered into a patent and know-how license agreement (the “EP Software Agreement”) with Mayo Foundation for Medical Education and Research (“Mayo”). The EP Software Agreement grants to the Company an exclusive worldwide license, with the right to sublicense, within the field of electrophysiology software and under certain patent rights as described in the EP Software Agreement (the “Patent Rights”), to make, have made, use, offer for sale, sell and import licensed products and a non-exclusive license to the Company to use the research and development information, materials, technical data, unpatented inventions, trade secrets, know-how and supportive information of Mayo to develop, make, have made, use, offer for sale, sell, and import licensed products. The EP Software Agreement will expire upon the later of either (a) the expiration of the Patent Rights or (b) the 10th anniversary of the date of the first commercial sale of a licensed product, unless earlier terminated by Mayo for the Company’s failure to cure a material breach of the EP Software Agreement, the Company’s or a sublicensee’s commencement of any action or proceedings against Mayo or its affiliates other than for an uncured material breach of the EP Software Agreement by Mayo, or insolvency of the Company. In connection with the EP Software Agreement, the Company issued to Mayo an 8-year warrant (the “EP Software Warrant”) to purchase 284,455 shares of the Company’s common stock at an exercise price of $6.16. The EP Software Warrant is immediately exercisable and may be exercised on a cashless basis if there is no effective registration statement registering or a current prospectus available for the resale of the shares underlying the EP Software Warrant. The Company agreed to pay Mayo an upfront consideration of $25,000. The Company also agreed to make earned royalty payments to Mayo in connection with the Company’s sales of the licensed products to third parties and sublicense income received by the Company and to make milestone payments of up to $625,000 in aggregate. Amended and Restated Patent and Know-How License Agreement Tools Agreement On November 20, 2019, the Company entered into an amended and restated patent and know-how license agreement (the “Tools Agreement”) with Mayo. The Tools Agreement contains terms of license grant substantially identical to the EP Software Agreement, although it is for different patent rights and covers the field of electrophysiology systems. In connection with the Tools Agreement, the Company issued to Mayo an 8-year warrant (the “Tools Warrant”) to purchase 284,455 shares of the Company’s common stock at an exercise price of $6.16. The Tools Warrant is immediately exercisable and may be exercised on a cashless basis if there is no effective registration statement registering or a current prospectus available for the resale of the shares underlying the Tools Warrant. The Company agreed to pay Mayo an upfront consideration of $100,000. The Company also agreed to make earned royalty payments to Mayo in connection with the Company’s sales of the licensed products to third parties and sublicense income received by the Company and to make milestone payments of up to $550,000 in aggregate. In June 2021, patent rights were issued (“Valid Claim”) as defined whereby the Company paid milestone one of $75,000. ViralClear Patent and Know-How License Agreement On November 20, 2019, the Company’s majority-owned subsidiary, ViralClear, entered into a patent and know-how license agreement (the “ViralClear Agreement”) with Mayo. The ViralClear Agreement contains terms of license grant substantially identical to the EP Software Agreement and the Tools Agreement, although it is for different patent rights and covers the field of stimulation and electroporation for hypotension/syncope management, renal and non-renal denervation for hypertension treatment, and for use in treatment of arrhythmias in the autonomic nervous system. In connection with the ViralClear Agreement, ViralClear issued to Mayo an 8-year warrant (the “ViralClear Warrant”) to purchase 473,772 shares of ViralClear’s common stock at an exercise price of $5.00 per share. The ViralClear Warrant is immediately exercisable and may be exercised on a cashless basis if there is no effective registration statement registering or a current prospectus available for the resale of the shares underlying the ViralClear Warrant. ViralClear agreed to pay Mayo an upfront consideration of $50,000. ViralClear also agreed to make earned royalty payments to Mayo in connection with ViralClear’s sales of the licensed products to third parties and sublicense income received by the Company and to make milestone payments of up to $700,000 in aggregate. In June 2021, patent rights were issued (“Valid Claim”) as defined whereby the Company paid milestone one of $75,000. Trek Therapeutics, PBC In the event of sublicensing, sale, transfer, assignment or similar transaction, ViralClear agreed to pay Trek 10% of the consideration received. As part of the acquired assets, ViralClear received an assignment and licensing rights agreement from Trek with a third-party vendor regarding certain formulas and compounds usage. The agreement calls for milestone payments upon marketing authorization (as amended and defined with respect of product in a particular jurisdiction in the territory, the receipt of all approvals from the relevant regulatory authority necessary to market and sell such product in any such jurisdiction, excluding any pricing approval or reimbursement authorization) in any first and second country of $10 million and $5 million, respectively, in addition to 6% royalty payments. Defined Contribution Plan Effective January 1, 2019, the Company established a qualified defined contribution plan (the “401(k) Plan”) pursuant to Section 401(k) of the Code, whereby all eligible employees may participate. Participants may elect to defer a percentage of their annual pretax compensation to the 401(k) plan, subject to defined limitations. The Company is required to make contributions to the 401(k) Plan equal to 3 percent of each participant’s eligible compensation, subject to limitations under the Code. For the year ended December 31, 2021 and 2020, the Company charged operations $252,452 and $170,317, respectively, for contributions under the 401(k) Plan. Purchase commitments As of December 31, 2021, the Company had aggregate purchase commitments of approximately $1,443,398 for future services or products, some of which are subject to modification or cancellations. Litigation Aurigene Pharmaceutical Services LTD vs. ViralClear Pharmaceuticals Inc. and BioSig Technologies, Inc. On January 8, 2021, Aurigene Pharmaceutical Services, LTD (“Aurigene”) filed a complaint with the United States District Court for the District of Connecticut claiming the Company is in default of certain milestone payments for manufacturing and services under contracts dated June 23, 2020 and July 16, 2020 in aggregate amount of $1,530,000. On September 23, 2021, the Company entered into a settlement agreement with Aurigene for a sum of $1,000,000 payable in three installments of $400,000, $300,000, and $300,000 on September 30, 2021, December 31, 2021 and March 31, 2022, respectively, with no admission or concession by either party. Balance due under the settlement is $600,000 as of December 31, 2021. In connection with the settlement, the Company recognized $553,000 gain on settlement of debt in the current period operations as the full amount was previously accrued. The Company is subject at times to other legal proceedings and claims, which arise in the ordinary course of its business. Although occasional adverse decisions or settlements may occur, the Company believes that the final disposition of such matters should not have a material adverse effect on its financial position, results of operations or liquidity.

SEGMENT REPORTING

SEGMENT REPORTING	12 Months Ended
	Dec. 31, 2021
Segment Reporting [Abstract]
Segment Reporting Disclosure [Text Block]	NOTE 12 SEGMENT REPORTING In accordance with ASC 280-10, the Company reports segment information based on the “management” approach. The management approach designates the internal reporting used by management for making decisions and assessing performance as the source of the Company’s reportable segments. The Company has three reportable segments: BioSig Technologies, Inc. (parent), NeuroClear Technologies, Inc. and ViralClear Pharmaceuticals, Inc. Information concerning the operations of the Company’s reportable segments is as follows: 2021 2020 Revenues (from external customers) BioSig $ 441 $ - ViralClear - - NeuroClear - - $ 441 $ - Operating Expenses BioSig $ 30,016 $ 30,756 ViralClear 3,630 28,387 NeuroClear 7 41 $ 33,653 $ 59,184 Income (loss) from operations BioSig $ (29,772 ) $ (30,727 ) ViralClear (3,077 ) (28,372 ) NeuroClear (7 ) (41 ) $ (32,856 ) $ (59,140 ) Total Assets BioSig $ 13,595 $ 24,764 ViralClear 1,924 5,622 NeuroClear - - $ 15,519 $ 30,386

RELATED PARTY TRANSACTIONS

RELATED PARTY TRANSACTIONS	12 Months Ended
	Dec. 31, 2021
Related Party Transactions [Abstract]
Related Party Transactions Disclosure [Text Block]	NOTE 13 RELATED PARTY TRANSACTIONS Accrued expenses related primarily to travel reimbursements, director fees and accrued compensation due related parties as of December 31, 2021 and 2020 was $86,208 and $317,000, respectively. On March 30, 2020, the Company’s subsidiary, ViralClear entered into an engagement agreement with Weild & Co, a FINRA-registered broker-dealer controlled by a member of the Company’s board of directors to act as ViralClear’s non-exclusive agent to provide investment banking and financial advisory services to assist ViralClear in a potential financing transaction for an initial term of 9 months. In connection with the engagement agreement, ViralClear agreed to pay Weild & Co a 5% cash and a 5% warrant or other securities of the aggregate subscriptions placed by Weild & Co. No costs have been incurred as of the date of this filing. No cash or warrant fees have been paid under this agreement. As described in Note 11, on March 24, 2020, ViralClear entered into the Asset Purchase Agreement with Trek Therapeutics, PBC, an entity controlled by a former member of the Company’s board of directors. Pursuant to the Asset Purchase Agreement, Trek sold to ViralClear all right, title and interest of Trek and its affiliates to certain assets. As consideration for the Purchased Assets, ViralClear agreed to pay Trek in upfront and milestone payments a combination of cash, shares of ViralClear’s common stock. In 2020, ViralClear issued an aggregate of 1,138,000 restricted stock units for shares in ViralClear’s common stock to board members and an officer. In 2020, ViralClear granted an aggregate of 746,507 options to purchase ViralClear’s common stock to members of ViralClear’s board of directors. On August 12, 2020, the Company cancelled the grant from March 31, 2020 to a board member for 50,000 options to purchase the Company’s common stock at an exercise price of $3.73 and granted the board member 50,000 shares of common stock at a cost basis of $7.10 per share for his assistance with ViralClear. The granted shares vested immediately. In 2020, the Company issued an aggregate of 175,000 shares of the Company’s common stock, 100,000 restricted stock units and 675,000 options to purchase the Company’s common stock to officers and directors. In 2020, the Company issued an aggregate of 4,030 shares of the Company’s common stock to a board member and an officer for the cashless exercise of options. On January 5, 2021, the Company issued an aggregate of 450,000 shares of common stock to officers of the Company as part of annual compensation. On June 28, 2021, in connection with the departure of two board members, the Company extended for up to two years 125,000 and 50,000 previously granted options that would normally expire 90 days after leaving service. On June 30, 2021, in connection with the resignation of a board member, the Company entered into a one-year consulting contract and extended for up to two years from end of contract service: 240,000 previously granted Company options, 25,000 previously granted ViralClear options and 329,000 previously issued ViralClear restricted stock units; all of which would normally expire 90 days after leaving service. In addition, the Company accelerated to fully vested previously issued restricted stock units and issued 50,000 shares of the Company’s common stock in settlement. On October 4, 2021, the Company granted a new board member 50,000 options to acquire the Company’s common stock at an exercise price of $2.89 for joining the Company’s Board of Directors. The options are exercisable for ten years with half vested immediately and half on September 20, 2022. On December 28, 2021, the Company granted an aggregate of 425,000 options to acquire the company’s common stock at an exercise price of $2.44 for ten years and vesting immediately to the Company’s existing Board of Directors as compensation for the 2021 year. During the years ended December 31, 2021 and 2020, the Company’s Chief Financial Officer guaranteed issued corporate credit cards for no consideration.

INCOME TAXES

INCOME TAXES	12 Months Ended
	Dec. 31, 2021
Income Tax Disclosure [Abstract]
Income Tax Disclosure [Text Block]	NOTE 14 INCOME TAXES At December 31, 2021, the Company has available for federal income tax purposes a net operating loss carry forward of approximately $116,000,000, expiring in the year 2039, that may be used to offset future taxable income. The Company has provided a valuation reserve against the full amount of the net operating loss benefit, since in the opinion of management based upon the earnings history of the Company; it is more likely than not that the benefits will not be realized. Due to possible significant changes in the Company’s ownership, the future use of its existing net operating losses may be limited. All or portion of the remaining valuation allowance may be reduced in future years based on an assessment of earnings sufficient to fully utilize these potential tax benefits. During the year ended December 31, 2021, the Company has increased the valuation allowance by $6,470,000 from $24,700,000 to $31,170,000. We have adopted the provisions of ASC 740-10-25, which provides recognition criteria and a related measurement model for uncertain tax positions taken or expected to be taken in income tax returns. ASC 740-10-25 requires that a position taken or expected to be taken in a tax return be recognized in the financial statements when it is more likely than not that the position would be sustained upon examination by tax authorities. Tax position that meet the more likely than not threshold is then measured using a probability weighted approach recognizing the largest amount of tax benefit that is greater than 50% likely of being realized upon ultimate settlement. The Company had no tax positions relating to open income tax returns that were considered to be uncertain. The Company is required to file income tax returns in the U.S. Federal various State jurisdictions. The Company is no longer subject to income tax examinations by tax authorities for tax years ending before December 31, 2015. The effective rate differs from the statutory rate of 21% as of December 31, 2021 and 2020 due to the following: December 31, 2021 December 31, 2020 Statutory rate on pre-tax book loss 21.00 % (21.00 )% Stock based compensation 0.0 % 8.10 % Fair value of warrant to acquire research and development 0.0 % 1.59 % Other (1.3 )% 0.03 % Valuation allowance (19.7 )% 11.28 % 0.00 % 0.00 % The Company’s deferred taxes as of December 31, 2021 and 2020 consist of the following: December 31, 2021 December 31, 2020 Non-Current deferred tax asset: Net operating loss carry-forwards $ 24,308,000 $ 19,900,000 Stock based compensation 6,862,000 4,800,000 Valuation allowance (31,170,000 ) (24,700,000 ) Net non-current deferred tax asset $ - $ -

FAIR VALUE MEASUREMENT

FAIR VALUE MEASUREMENT	12 Months Ended
	Dec. 31, 2021
Fair Value Disclosures [Abstract]
Fair Value Disclosures [Text Block]	NOTE 15 FAIR VALUE MEASUREMENT The Company adopted the provisions of Accounting Standards Codification subtopic 825-10, Financial Instruments (“ASC 825-10”). ASC 825-10 defines fair value as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities required or permitted to be recorded at fair value, the Company considers the principal or most advantageous market in which it would transact and considers assumptions that market participants would use when pricing the asset or liability, such as inherent risk, transfer restrictions, and risk of nonperformance. ASC 825-10 establishes a fair value hierarchy that requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 825-10 establishes three levels of inputs that may be used to measure fair value: Level 3 – Unobservable inputs to the valuation methodology that are significant to the measurement of fair value of assets or liabilities. All items required to be recorded or measured on a recurring basis are based upon level 3 inputs. To the extent that valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. In certain cases, the inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, for disclosure purposes, the level in the fair value hierarchy within which the fair value measurement is disclosed and is determined based on the lowest level input that is significant to the fair value measurement. The carrying value of the Company’s cash and cash equivalents, accounts payable and other current assets and liabilities approximate fair value because of their short-term maturity. As of December 31, 2021, and 2020, the Company did not have any items that would be classified as level 1, 2 or 3 disclosures. As of December 31, 2021, and 2020, the Company did not have any derivative instruments that were designated as hedges. There were no derivative and warrant liabilities as of December 31, 2021 and 2020.

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	12 Months Ended
	Dec. 31, 2021
Subsequent Events [Abstract]
Subsequent Events [Text Block]	NOTE 16 SUBSEQUENT EVENTS Equity financing: On March 22, 2022, the Company closed a registered direct offering (the “Offering”) of an aggregate of 2,613,130 shares of our common stock, at an offering price of $1.15 per share and (ii) warrants to purchase up to 2,613,130 shares of our common stock, at an exercise price of $1.40 per share, that will become exercisable six months after the date of issuance and will expire three and one-half years following the date of issuance, for gross proceeds of approximately $3.0 million before the deduction of fees and offering expenses. The common stock and warrants were offered by the Company pursuant to a shelf registration statement on Form S-3 (File No. 333-251859) (the “Shelf Registration Statement”), previously filed with the SEC on December 31, 2020, and declared effective by the SEC on January 12, 2021, and a prospectus supplement, dated March 21, 2022, to the Shelf Registration Statement, filed with the SEC on March 22, 2022. Equity transactions: On January 3, 2022, the Company issued an aggregate of 75,000 shares of its common stock for services previously granted and accrued on December 29, 2021 valued at $167,250. On January 4, 2022, the Company issued an aggregate of 53,749 shares of its common stock for previously issued vested restricted stock units. On January 27, 2022, The Company issued an aggregate of 40,000 shares of its common stock for services valued at $72,800. On February 1, 2022, the Company issued a 25,000 restricted stock unit to a consultant for services rendered with 12,500 shares vesting immediately and 12,500 shares vesting upon completion of certain milestones valued at $56,750. The vested shares of 12,500 were issued on February 1, 2022. On February 15, 2022, the Company issued 12,500 shares of its common stock for a previously issued restricted stock units. On February 7, 2022, the Company granted an aggregate of 250,000 options to purchase shares of its common stock to consultants. The options are exercisable at $1.72 per share for ten years with (i) 100,000 options vesting in equal quarterly installments over one year, and (ii) 150,000 options vesting 50% at grant date and 50% upon milestone of $7 million revenue. On February 17, 2022, the Company granted 30,000 options to purchase shares of its common stock to a consultant. The options are exercisable at $1.58 per share for ten years vesting in equal quarterly installments over one year. On February 17, 2022, the Company granted an aggregate of 36,000 options to purchase shares of its common stock to two employees. The options are exercisable at $1.58 per share for ten years with one-third vesting on the first anniversary of the date of grant, and the remaining two-thirds vesting in substantially equal quarterly installments over the following two years. In March 2022, the Company issued a 25,000 restricted stock unit to a consultant for services rendered. The restricted stock unit vests quarterly over one year and valued at $56,750. On March 15, 2022, BioSig granted an aggregate of 70,000 options to purchase shares of its common stock to three employees. The options are exercisable at $1.28 per share for ten years with one-third vesting on the first anniversary of the date of grant, and the remaining two-thirds vesting in substantially equal quarterly installments over the following two years. On March 21, 2022, the Company issued 50,000 shares of its common stock to an officer for services valued at $70,000. On March 30, 2022, the Company granted 350,000 options to purchase shares of its common stock an employee. The options are exercisable at $1.30 per share for ten years with one-third vesting on the first anniversary of the date of grant, and the remaining two-thirds vesting in substantially equal quarterly installments over the following two years.

Accounting Policies, by Policy

Accounting Policies, by Policy (Policies)	12 Months Ended
	Dec. 31, 2021
Accounting Policies [Abstract]
Consolidation, Policy [Policy Text Block]	Principals of consolidation The accompanying consolidated financial statements include the accounts of BioSig Technologies, Inc. and its majority owned subsidiary, ViralClear Pharmaceuticals, Inc., and wholly owned subsidiary, NeuroClear Technologies, Inc. herein referred to as the “Company” or “BioSig”. All significant intercompany accounts and transactions have been eliminated in consolidation.
Use of Estimates, Policy [Policy Text Block]	Use of Estimates The preparation of these consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Significant estimates include the recoverability and useful lives of long-lived assets, fair value of acquired assets, stock-based compensation and the valuation allowance related to deferred tax assets. Actual results may differ from these estimates.
Revenue [Policy Text Block]	Revenue Recognition The Company derives its revenue primarily from the sale of its medical device, the PURE EP™ System, and well as related support and maintenance services and software upgrades in connection with the system. The Company recognizes revenue in accordance with Accounting Standards Codification (ASC) 606, Revenue from Contracts with Customers the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The Company determines revenue recognition through the following five steps: ● Identify the contract with the customer; ● Identify the performance obligations in the contract; ● Determine the transaction price; ● Allocate the transaction price to the performance obligation in the contract; and ● Recognize revenue when, or as, the performance obligations are satisfied. Performance obligations are the unit of accounting for revenue recognition and generally represent the distinct goods or services that are promised to the customer. If the Company determines that it has not satisfied a performance obligation, it will defer recognition of the revenue until the performance obligation is deemed to be satisfied. Once the PURE EP system is delivered, installed, and accepted by the customer, our performance obligation is recognized. Support, maintenance, and software upgrades are performance obligations over a defined period and are recognized ratably over the contractual service period. Customers typically purchase these services with the initial sale of the PURE EP System and do not have the right to terminate their contracts unless we fail to perform material obligations. The Company may execute more than one contract with a single customer. If so, it is evaluated whether the agreements were negotiated as a package with a single objective, whether the amount of consideration to be paid in one agreement depends on the price and/or performance of another agreement, or whether the goods or services promised in the agreements represent a single performance obligation. The conclusions reached can impact the allocation of the transaction price to each performance obligation and the timing of revenue recognition related to those arrangements. The Company records accounts receivable for amounts invoiced to customers for which the Company has an unconditional right to consideration as provided under the contractual arrangement. Unbilled receivables, if any, include amounts related to the Company’s contractual right to consideration for completed performance obligations not yet invoiced. Deferred revenue includes payments received in advance of performance under the contract. Our unbilled receivables and deferred revenue are reported on an individual contract basis at the end of each reporting period. Unbilled receivables are classified as current or noncurrent based on the timing of when we expect to bill the customer. Deferred revenue is classified as current or noncurrent based on the timing of when we expect to recognize revenue. The Company’s unconditional right to consideration for goods and services transferred to the customer is included in accounts receivable, net (if any) in the Company’s consolidated balance sheet. There are no contract liabilities for the year ended December 31, 2020. A reconciliation of contract liabilities with customers for the year ended December 31, 2021, are presented below: Balance at December 31, 2020 (000’s) Consideration Received (000’s) Recognized in Revenue (000’s) Balance at December 31, 2021 (000’s) Product revenue $ - $ 414 $ (414 ) $ - Service revenue - 64 (27 ) 37 Total $ - $ 478 $ (441 ) $ 37 The table below summarizes our deferred revenue as of December 31, 2021 and 2020: December 31, 2021 (000’s) December 31, 2020 (000’s) Deferred revenue-current $ 32 $ - Deferred revenue-noncurrent 5 - Total deferred revenue $ 37 $ - The Company had two customers which accounted for approximately 68% and 32% of their revenue in the year ended December 31, 2021. The Company utilized one contract manufacturer for the manufacture and supply of the Pure EP system for the years ended December 31, 2021 and 2020.
Cost of Goods and Service [Policy Text Block]	Cost of Goods Sold Cost of goods sold consists primarily of the delivered cost of our medical device(s) sold.
Receivables, Trade and Other Accounts Receivable, Allowance for Doubtful Accounts, Policy [Policy Text Block]	Allowance for Doubtful Accounts The Company adjusts accounts receivable down to net realizable value with its allowance methodology. In determining the allowance for doubtful accounts for estimated losses, aged receivables are analyzed periodically by management. Each identified receivable is reviewed based upon historical collection experience, financial condition of the client and the status of any open or unresolved issues with the client preventing the payment thereof. Corrective action, if necessary, is taken by the Company to resolve open issues related to unpaid receivables. The allowance for doubtful accounts was $0 at December 31, 2021 and 2020. The Company believes that its reserve is adequate, however results may differ in future periods. For the year ended December 31, 2021 and 2020, bad debt expense totaled $0.
Fair Value of Financial Instruments, Policy [Policy Text Block]	Fair Value of Financial Instruments Accounting Standards Codification subtopic 825-10, Financial Instruments (“ASC 825-10”) requires disclosure of the fair value of certain financial instruments. The carrying value of cash, accounts payable and accrued liabilities as reflected in the balance sheets, approximate fair value because of the short-term maturity of these instruments. All other significant financial assets, financial liabilities and equity instruments of the Company are either recognized or disclosed in the financial statements together with other information relevant for making a reasonable assessment of future cash flows, interest rate risk and credit risk. Where practicable the fair values of financial assets and financial liabilities have been determined and disclosed; otherwise only available information pertinent to fair value has been disclosed. The Company follows Accounting Standards Codification subtopic 820-10, Fair Value Measurements and Disclosures (“ASC 820-10”) and ASC 825-10, which permits entities to choose to measure many financial instruments and certain other items at fair value.
Concentration Risk, Credit Risk, Policy [Policy Text Block]	Concentrations of Credit Risk Financial instruments and related items, which potentially subject the Company to concentrations of credit risk, consist primarily of cash and cash equivalents. The Company places its cash and temporary cash investments with credit quality institutions. At times, such amounts may be in excess of the FDIC insurance limit. At December 31, 2021 and 2020, deposits in excess of FDIC limits were $11.2 million and $27.8 million, respectively.
Inventory, Policy [Policy Text Block]	Inventory The inventory is comprised of work in process and finished goods available for sale and are stated at the lower of cost or net realizable value using specific identification method for serial numbered inventory and first-in, first-out method for all other inventory for valuation. The inventory at December 31, 2021 and 2020 were $1.9 million and $0.8 million, respectively, comprised of finished goods.
Prepaid Expenses Policy [Policy Text Block]	Prepaid Expenses and Vendor Deposits Prepaid expenses and vendor deposits are comprised of prepaid insurance, operating expenses and other prepayments.
Lessee, Leases [Policy Text Block]	Leases The Company determines if a contractual arrangement is a lease at inception. Operating leases are included in operating lease right-of-use (“ROU”) assets, current operating lease liabilities, and noncurrent operating lease liabilities on the Company’s consolidated balance sheet. The Company evaluates and classifies leases as operating or finance leases for financial reporting purposes. The classification evaluation begins at the commencement date and the lease term used in the evaluation includes the non-cancellable period for which the Company has the right to use the underlying asset, together with renewal option periods when the exercise of the renewal option is reasonably certain and failure to exercise such option which result in an economic penalty. All the Company’s real estate leases are classified as operating leases. ROU assets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent the Company’s obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at the commencement date of the lease based on the present value of lease payments over the lease term. The lease payments included in the present value are fixed lease payments. As most of the Company’s leases do not provide an implicit rate, the Company estimates its collateralized incremental borrowing rate, based on information available at the commencement date, in determining the present value of lease payments. The Company applies the portfolio approach in applying discount rates to its classes of leases. The operating lease ROU assets include any payments made before the commencement date. Lease expense for lease payments is recognized on a straight-line basis over the lease term. The Company does not currently have subleases. The Company does not currently have residual value guarantees or restrictive covenants in its leases.
Property, Plant and Equipment, Policy [Policy Text Block]	Property and Equipment Property and equipment are stated at cost and depreciated using the straight-line method over their estimated useful lives of 3 to 5 years. When retired or otherwise disposed, the related carrying value and accumulated depreciation are removed from the respective accounts and the net difference less any amount realized from disposition, is reflected in earnings.
Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]	Impairment of Long-lived Assets The Company recognizes an impairment of long-lived assets used in operations, other than goodwill, when events or circumstances indicate that the asset might be impaired and the estimated undiscounted cash flows to be generated by those assets over their remaining lives are less than the carrying amount of those items. The net carrying value of assets not recoverable is reduced to fair value, which is typically calculated using the discounted cash flow method. The Company did not recognize and record any impairments of long-lived assets used in operations during the years ended December 31, 2021 and 2020.
Research and Development Expense, Policy [Policy Text Block]	Research and Development Costs The Company accounts for research and development costs in accordance with the Accounting Standards Codification subtopic 730-10, Research and Development (“ASC 730-10”). Under ASC 730-10, all research and development costs must be charged to expense as incurred. Accordingly, internal research and development costs are expensed as incurred. Third-party research and developments costs are expensed when the contracted work has been performed or as milestone results have been achieved. Company-sponsored research and development costs related to both present and future products are expensed in the period incurred. The Company incurred research and development expenses of $5.6 million and $18.1 million for the year ended December 31, 2021 and 2020, respectively.
Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block]	Acquisition of Intellectual Property Intellectual property acquired are accounted for under the acquisition method of accounting. This method requires the recording of acquired assets, including separately identifiable intangible assets, and assumed liabilities at their acquisition date fair values. Any excess consideration transferred over fair value is allocated on a relative fair value basis to the identifiable net assets. The acquired intellectual property from the Trek acquisition was considered unproven compounds, the success of which was uncertain at the time of the acquisition. Accordingly, the fair value of the consideration paid was charged as acquired research and development to current period operations.
Earnings Per Share, Policy [Policy Text Block]	Net Income (loss) Per Common Share The Company computes earnings (loss) per share under Accounting Standards Codification subtopic 260-10, Earnings Per Share (“ASC 260-10”). Net loss per common share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the period. Diluted earnings per share, if presented, would include the dilution that would occur upon the exercise or conversion of all potentially dilutive securities into common stock using the “treasury stock” and/or “if converted” methods as applicable. The computation of basic and diluted loss per share as of December 31, 2021 and 2020 excludes potentially dilutive securities when their inclusion would be anti-dilutive, or if their exercise prices were greater than the average market price of the common stock during the period. Potentially dilutive securities excluded from the computation of basic and diluted net income (loss) per share are as follows: December 31, 2021 December 31, 2020 Series C convertible preferred stock 83,468 47,578 Options to purchase common stock 4,568,484 3,568,497 Warrants to purchase common stock 818,910 1,446,200 Restricted stock units to acquire common stock 141,250 218,334 Totals 5,612,112 5,280,609
Share-based Payment Arrangement [Policy Text Block]	Stock Based Compensation The Company measures the cost of services received in exchange for an award of equity instruments based on the fair value of the award as measured on the grant date. The fair value amount is then recognized over the period during which services are required to be provided in exchange for the award, usually the vesting period.
Income Tax, Policy [Policy Text Block]	Income Taxes The Company follows Accounting Standards Codification subtopic 740-10, Income Taxes (“ASC 740-10”) for recording the provision for income taxes. Deferred tax assets and liabilities are computed based upon the difference between the financial statement and income tax basis of assets and liabilities using the enacted marginal tax rate applicable when the related asset or liability is expected to be realized or settled. Deferred income tax expenses or benefits are based on the changes in the asset or liability during each period. If available evidence suggests that it is more likely than not that some portion or all of the deferred tax assets will not be realized, a valuation allowance is required to reduce the deferred tax assets to the amount that is more likely than not to be realized. Future changes in such valuation allowance are included in the provision for deferred income taxes in the period of change. Deferred income taxes may arise from temporary differences resulting from income and expense items reported for financial accounting and tax purposes in different periods.
Intangible Assets, Finite-Lived, Policy [Policy Text Block]	Patents, Net The Company capitalizes certain initial asset costs in connection with patent applications including registration, documentation and other professional fees associated with the application. Patent costs incurred prior to the Company’s U.S. Food and Drug Administration (“FDA”) 510(k) application on March 28, 2018 were charged to research and development expense as incurred. Commencing upon first in-man trials on February 18 and 19, 2019, capitalized costs are amortized to expense using the straight-line method over the lesser of the legal patent term or the estimated life of the product of 20 years. During the year ended December 31, 2021 and 2020, the Company recorded amortization of $19,006 and $19,005 to current period operations, respectively.
Standard Product Warranty, Policy [Policy Text Block]	Warranty The Company generally warrants its products to be free from material defects and to conform to material specifications for a period of up to two (2) years. Warranty expense is estimated based primarily on historical experience and is reflected in the consolidated financial statements.
Consolidation, Subsidiaries or Other Investments, Consolidated Entities, Policy [Policy Text Block]	Non-controlling Interest The Company’s non-controlling interest represents the non-controlling shareholders ownership interests related to the Company’s subsidiary, ViralClear. The Company reports its non-controlling interest in subsidiaries as a separate component of equity in the consolidated balance sheets and reports both net loss attributable to the non-controlling interest and net loss attributable to the Company’s common shareholders on the face of the consolidated statements of operations. The Company’s equity interest in ViralClear is 68.44% and the non-controlling stockholders’ interest is 31.56% as of December 31, 2021. This is reflected in the consolidated statements of changes in equity.
Segment Reporting, Policy [Policy Text Block]	Segment Information Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision maker, or decision-making group, in making decisions how to allocate resources and assess performance. The information disclosed herein represents all of the material financial information related to the Company’s principal operating segments. (See Note 12 – Segment Reporting).
New Accounting Pronouncements, Policy [Policy Text Block]	Recent Accounting Pronouncements In June 2016, the FASB issued ASU 2016-13, Financial Instruments-Credit Losses : Measurement of Credit Losses on Financial Instruments In February 2020, the FASB issued ASU 2020-02, Financial Instruments-Credit Losses and Leases Amendments to SEC Paragraphs Pursuant to SEC Staff Accounting Bulletin No. 119 and Update to SEC Section on Effective Date Related to Accounting Standards Update No. 2016-02, Leases There were other various updates recently issued, most of which represented technical corrections to the accounting literature or application to specific industries and are not expected to a have a material impact on the Company’s financial position, results of operations or cash flows.

SUMMARY OF SIGNIFICANT ACCOUN_2

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)	12 Months Ended
	Dec. 31, 2021
Accounting Policies [Abstract]
Disaggregation of Revenue [Table Text Block]	A reconciliation of contract liabilities with customers for the year ended December 31, 2021, are presented below: Balance at December 31, 2020 (000’s) Consideration Received (000’s) Recognized in Revenue (000’s) Balance at December 31, 2021 (000’s) Product revenue $ - $ 414 $ (414 ) $ - Service revenue - 64 (27 ) 37 Total $ - $ 478 $ (441 ) $ 37
Deferred Revenue, by Arrangement, Disclosure [Table Text Block]	The table below summarizes our deferred revenue as of December 31, 2021 and 2020: December 31, 2021 (000’s) December 31, 2020 (000’s) Deferred revenue-current $ 32 $ - Deferred revenue-noncurrent 5 - Total deferred revenue $ 37 $ -
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	Potentially dilutive securities excluded from the computation of basic and diluted net income (loss) per share are as follows: December 31, 2021 December 31, 2020 Series C convertible preferred stock 83,468 47,578 Options to purchase common stock 4,568,484 3,568,497 Warrants to purchase common stock 818,910 1,446,200 Restricted stock units to acquire common stock 141,250 218,334 Totals 5,612,112 5,280,609

PROPERTY AND EQUIPMENT (Tables)

PROPERTY AND EQUIPMENT (Tables)	12 Months Ended
	Dec. 31, 2021
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment [Table Text Block]	Property and equipment as of December 31, 2021 and 2020 is summarized as follows: December 31, 2021 (000’s) December 31, 2020 (000’s) Computer equipment $ 383 $ 234 Furniture and fixtures 88 75 Manufacturing equipment 286 34 Testing/Demo equipment 145 96 Leasehold improvements 79 - Total 981 439 Less accumulated depreciation (329 ) (150 ) Property and equipment, net $ 652 $ 289

RIGHT TO USE ASSETS AND LEASE_2

RIGHT TO USE ASSETS AND LEASE LIABILITY (Tables)	12 Months Ended
	Dec. 31, 2021
RIGHT TO USE ASSETS AND LEASE LIABILITY (Tables) [Line Items]
Right to Use Asset [Table Text Block]	Right to use assets is summarized below: December 31, 2021 (000’s) December 31, 2020 (000’s) Right to use assets, net $ 803 $ 1,087 Less accumulated amortization (199 ) (781 ) Right to use assets, net $ 604 $ 306
Lessee, Operating Lease, Liability, Maturity [Table Text Block]	Maturity analysis under these lease agreements are as follows (000’s): Year ended December 31, 2022 $ 304 Year ended December 31, 2023 221 Year ended December 31, 2024 191 Total 716 Less: Present value discount (60 ) Lease liability $ 656
Operating Lease [Member]
RIGHT TO USE ASSETS AND LEASE LIABILITY (Tables) [Line Items]
Lease, Cost [Table Text Block]	Lease liability is summarized below: December 31, 2021 (000’s) December 31, 2020 (000’s) Total lease liability $ 656 $ 314 Less: short term portion (283 ) (313 ) Long term portion $ 373 $ 1
Finance Lease [Member]
RIGHT TO USE ASSETS AND LEASE LIABILITY (Tables) [Line Items]
Lease, Cost [Table Text Block]	Lease expense for the year ended December 31, 2021 and 2020 was comprised of the following: December 31, 2021 (000’s) December 31, 2020 (000’s) Operating lease expense $ 441 $ 456 Short-term lease expense 39 35 Variable lease expense - 2 Total $ 480 $ 493

ACCOUNTS PAYABLE AND ACCRUED _2

ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Tables)	12 Months Ended
	Dec. 31, 2021
Payables and Accruals [Abstract]
Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]	Accounts payable and accrued expenses at December 31, 2021 and 2020 consist of the following: December 31, 2021 (000’s) December 31, 2020 (000’s) Accrued accounting and legal $ 204 $ 177 Accrued reimbursements and travel 56 56 Accrued consulting 264 256 Accrued research and development expenses 367 3,127 Accrued product purchases 1 30 Accrued marketing 38 - Accrued office and other 84 127 Accrued payroll 552 936 Accrued settlement related to arbitration 613 13 $ 2,179 $ 4,722

OPTIONS, RESTRICTED STOCK UNI_2

OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Tables)	12 Months Ended
	Dec. 31, 2021
OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Tables) [Line Items]
Share-based Payment Arrangement, Option, Exercise Price Range [Table Text Block]	The following table presents information related to stock options at December 31, 2021: Options Outstanding Options Exercisable Weighted Average Exercisable Exercise Number of Remaining Life Number of Price Options In Years Options $ Under 3.00 1,035,375 9.5 560,000 3.00-3.99 587,466 6.5 387,466 4.00-4.99 1,762,916 6.2 1,151,545 5.00-5.99 156,132 7.1 119,464 6.00-6.99 591,542 5.0 478,846 7.00-7.99 191,720 6.9 177,138 Over 8.00 243,333 6.3 197,351 4,568,484 6.9 3,071,810 Options Outstanding Options Exercisable Weighted Average Exercisable Exercise Number of Remaining Life Number of Price Options In Years Options $ 5.00 125,000 7.2 83,331
Share-based Payment Arrangement, Option, Activity [Table Text Block]	A summary of the stock option activity and related information for the Plan for the two years ended December 31, 2021 is as follows: Weighted-Average Weighted-Average Remaining Aggregate Shares Exercise Price Contractual Term Intrinsic Value Outstanding at January 1, 2020 3,980,804 $ 5.58 6.3 $ 3,130,791 Grants 1,120,000 $ 4.98 10.0 - Exercised (1,203,223 ) $ 5.08 Forfeited/expired (329,084 ) $ 5.19 Outstanding at December 31, 2020 3,568,497 $ 5.59 7.0 $ 110,961 Grants 1,818,000 $ 3.69 10.0 $ - Exercised (9,375 ) $ 2.96 Forfeited/expired (808,638 ) $ 6.19 Outstanding at December 31, 2021 4,568,484 $ 4.57 6.9 $ - Exercisable at December 31, 2021 3,071,810 $ 4.83 6.0 $ -
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	The following assumptions were used in determining the fair value of options during the years ended December 31, 2021 and 2020: 2021 2020 Risk-free interest rate 0.77% - 1.49 % 0.42% to 1.83 % Dividend yield 0 % 0 % Stock price volatility 82.50% to 95.98 % 86.51% to 93.43 % Expected life 5 – 10 years 5-10 years Weighted average grant date fair value $ 2.55 $ 4.03 Risk-free interest rate 0.05% - 0.25 % Dividend yield 0 % Stock price volatility 88.57 % Expected life 0.25 – 2 years Risk-free interest rate 0.06% - 0.46 % Dividend yield 0 % Stock price volatility 88.59 % Expected life 0.59 – 3 years Risk-free interest rate 0.36% to 0.52 % Dividend yield 0 % Stock price volatility 125.16% to 126.03 % Expected life 5 – 6 years Weighted average grant date fair value $ 4.51 Risk-free interest rate 0.07% - 0.46 % Dividend yield 0 % Stock price volatility 88.59 % Expected life 1.25 - 3 years
Schedule of Warrants or Rights, Shares Authorized, by Exercise Price Range [Table Text Block]	The following table summarizes information with respect to outstanding warrants to purchase common stock of BioSig Technologies, Inc. at December 31, 2021: Exercise Number Expiration Price Outstanding Date $ 4.80 250,000 February 2025 to July 2026 $ 6.16 568,910 November 2027 818,910
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]	A summary of the warrant activity for the two years ended December 31, 2021 is as follows: Weighted-Average Weighted-Average Remaining Aggregate Shares Exercise Price Contractual Term Intrinsic Value Outstanding at January 1, 2020 2,744,718 $ 5.40 2.2 $ 3,410,763 Issued 125,000 $ 4.80 4.2 - Exercised (580,487 ) $ 3.89 Expired (843,031 ) $ 6.29 Outstanding at December 31, 2020 1,446,200 $ 5.44 3.3 $ 1,500 Issued 125,000 $ 4.80 5.0 Expired (752,290 ) $ 5.00 - - Outstanding at December 31, 2021 818,910 $ 5.74 5.3 $ - Vested and expected to vest at December 31, 2021 818,910 $ 5.74 5.3 $ - Exercisable at December 31, 2021 818,910 $ 5.74 5.3 $ -
Nonvested Restricted Stock Shares Activity [Table Text Block]	The following table summarizes the restricted stock activity for the two years ended December 31, 2021: Restricted shares issued as of January 1, 2020 262,668 Granted 175,000 Vested and issued (219,334 ) Restricted shares issued as of December 31, 2020 218,334 Granted 301,000 Vested and issued (258,084 ) Forfeited (120,000 ) Vested restricted shares as of December 31, 2021 - Unvested restricted shares as of December 31, 2021 141,250 Restricted shares outstanding at January 1, 2020: 40,000 Granted 1,380,716 Restricted shares outstanding at December 31, 2020: 1,420,716 Issued (40,000 ) Forfeited (62,037 ) Total restricted shares outstanding at December 31, 2021: 1,318,679 Comprised of: Vested restricted shares as of December 31, 2021 678,679 Unvested restricted shares as of December 31, 2021 640,000 Total 1,318,679
Schedule of Warrants or Rights, Shares Authorized, Exercise Price Range [Table Text Block]	The following table presents information related to warrants (ViralClear) at December 31, 2021: Exercise Number Expiration Price Outstanding Date $ 5.00 473,772 November 2027 10.00 6,575 May 2025 480,347
Viral Clear [Member]
OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Tables) [Line Items]
Share-based Payment Arrangement, Option, Activity [Table Text Block]	A summary of the stock option activity and related information for the ViralClear Plan for the two years ended December 31, 2021 is as follows: Weighted-Average Weighted-Average Remaining Shares Exercise Price Contractual Term Outstanding at January 1, 2020 575,000 $ 5.00 9.3 Grants 1,599,173 $ 5.31 9.6 Forfeited/expired (646,507 ) $ 5.77 Outstanding at December 31, 2020 1,527,666 $ 5.00 4.0 Exercised (550,000 ) $ 5.00 Forfeited/expired (852,666 ) $ 5.00 Outstanding at December 31, 2021 125,000 $ 5.00 7.2 Exercisable at December 31, 2021 83,331 $ 5.00 6.6

NON-CONTROLLING INTEREST (Table

NON-CONTROLLING INTEREST (Tables)	12 Months Ended
	Dec. 31, 2021
Noncontrolling Interest [Abstract]
Schedule of Non-Controlling Interest [Table Text Block]	Net loss $ (3,077 ) Average Non-controlling interest percentage of profit/losses 30.44 % Net loss attributable to the non-controlling interest $ (939 ) Net loss $ (28,372 ) Average Non-controlling interest percentage of profit/losses 24.40 % Net loss attributable to the non-controlling interest $ (6,922 )
Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Table Text Block]	The following table summarizes the changes in non-controlling interest for the two years ended December 31, 2021 (000’s): Balance, January 1, 2020 $ 515 Allocation of equity to non-controlling interest due to equity-based compensation issued 2,782 Allocation of equity to non-controlling interest due to sale of common stock 3,468 Allocation of equity to non-controlling interest due to issuance of equity to acquire Trek and research and development 983 Allocation of equity from non-controlling interest due to parent reacquiring shares shareholders (24 ) Net loss attributable to non-controlling interest (6,922 ) Balance, December 31, 2020 802 Allocation of equity to non-controlling interest due to equity-based compensation issued 348 Allocation of equity to non-controlling interest to due change in fair value of modified option 8 Net loss attributable to non-controlling interest (939 ) Balance, December 31, 2021 $ 219

SEGMENT REPORTING (Tables)

SEGMENT REPORTING (Tables)	12 Months Ended
	Dec. 31, 2021
Segment Reporting [Abstract]
Schedule of Segment Reporting Information, by Segment [Table Text Block]	Information concerning the operations of the Company’s reportable segments is as follows: 2021 2020 Revenues (from external customers) BioSig $ 441 $ - ViralClear - - NeuroClear - - $ 441 $ - Operating Expenses BioSig $ 30,016 $ 30,756 ViralClear 3,630 28,387 NeuroClear 7 41 $ 33,653 $ 59,184 Income (loss) from operations BioSig $ (29,772 ) $ (30,727 ) ViralClear (3,077 ) (28,372 ) NeuroClear (7 ) (41 ) $ (32,856 ) $ (59,140 ) Total Assets BioSig $ 13,595 $ 24,764 ViralClear 1,924 5,622 NeuroClear - - $ 15,519 $ 30,386

INCOME TAXES (Tables)

INCOME TAXES (Tables)	12 Months Ended
	Dec. 31, 2021
Income Tax Disclosure [Abstract]
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]	The effective rate differs from the statutory rate of 21% as of December 31, 2021 and 2020 due to the following: December 31, 2021 December 31, 2020 Statutory rate on pre-tax book loss 21.00 % (21.00 )% Stock based compensation 0.0 % 8.10 % Fair value of warrant to acquire research and development 0.0 % 1.59 % Other (1.3 )% 0.03 % Valuation allowance (19.7 )% 11.28 % 0.00 % 0.00 %
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]	The Company’s deferred taxes as of December 31, 2021 and 2020 consist of the following: December 31, 2021 December 31, 2020 Non-Current deferred tax asset: Net operating loss carry-forwards $ 24,308,000 $ 19,900,000 Stock based compensation 6,862,000 4,800,000 Valuation allowance (31,170,000 ) (24,700,000 ) Net non-current deferred tax asset $ - $ -

NATURE OF OPERATIONS AND BASI_2

NATURE OF OPERATIONS AND BASIS OF PRESENTATION (Details) - Viral Clear [Member] $ in Millions	24 Months Ended
	Dec. 31, 2020USD ($)shares
NATURE OF OPERATIONS AND BASIS OF PRESENTATION (Details) [Line Items]
Stock Issued During Period, Shares, New Issues	1,965,240
Stock Issued During Period, Value, New Issues (in Dollars) | $	$ 15.6
Stockholders' Equity, Other Shares	894,869
Equity Method Investment, Ownership Percentage	68.44%

GOING CONCERN AND MANAGEMENT'_2

GOING CONCERN AND MANAGEMENT'S LIQUIDITY PLANS (Details) - USD ($)	Jun. 24, 2020	Feb. 25, 2020	Mar. 30, 2022	Dec. 31, 2021	Dec. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Cash and Cash Equivalents, at Carrying Value				$ 11,700,000
Working Capital (Deficit)				11,300,000
Proceeds from Issuance or Sale of Equity				10,300,000
Proceeds from Issuance of Common Stock	$ 16,161,980	$ 9,052,331	$ 3,000,000	9,004,000	$ 25,215,000
Net Cash Provided by (Used in) Operating Activities			$ 26,400,000	$ (26,399,000)	$ (26,601,000)

SUMMARY OF SIGNIFICANT ACCOUN_3

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]
Accounts Receivable, Credit Loss Expense (Reversal)	$ 0	$ 0
Cash, Uninsured Amount	11,200,000	27,800,000
Inventory, Net	1,881,000	768,000
Research and Development Expense	5,602,000	18,136,000
Amortization	$ 19,006	$ 19,005
Viral Clear [Member]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]
Noncontrolling Interest, Ownership Percentage by Parent	68.44%
Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners	31.56%
Patents [Member]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]
Finite-Lived Intangible Asset, Useful Life	20 years
Minimum [Member]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]
Property, Plant and Equipment, Useful Life	3 years
Maximum [Member]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]
Property, Plant and Equipment, Useful Life	5 years
Customer Concentration Risk [Member] | Revenue Benchmark [Member] | Two Customers [Member]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]
Concentration Risk, Percentage	68.00%	32.00%

SUMMARY OF SIGNIFICANT ACCOUN_4

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - Disaggregation of Revenue $ in Thousands	12 Months Ended
	Dec. 31, 2021USD ($)
Disaggregation of Revenue [Line Items]
Balance	$ 0
Consideration Received	478
Recognized in Revenue	(441)
Balance	37
Product [Member]
Disaggregation of Revenue [Line Items]
Balance	0
Consideration Received	414
Recognized in Revenue	(414)
Balance	0
Service [Member]
Disaggregation of Revenue [Line Items]
Balance	0
Consideration Received	64
Recognized in Revenue	(27)
Balance	$ 37

SUMMARY OF SIGNIFICANT ACCOUN_5

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - Deferred Revenue, by Arrangement, Disclosure - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Deferred Revenue, by Arrangement, Disclosure [Abstract]
Deferred revenue-current	$ 32	$ 0
Deferred revenue-noncurrent	5	0
Total deferred revenue	$ 37	$ 0

SUMMARY OF SIGNIFICANT ACCOUN_6

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share - shares	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities	5,612,112	5,280,609
Share-based Payment Arrangement, Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities	4,568,484	3,568,497
Warrant [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities	818,910	1,446,200
Restricted Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities	141,250	218,334
Series C Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities	83,468	47,578

PROPERTY AND EQUIPMENT (Details

PROPERTY AND EQUIPMENT (Details) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
PROPERTY AND EQUIPMENT (Details) [Line Items]
Depreciation	$ 179,136	$ 74,527
Minimum [Member]
PROPERTY AND EQUIPMENT (Details) [Line Items]
Property, Plant and Equipment, Useful Life	3 years
Maximum [Member]
PROPERTY AND EQUIPMENT (Details) [Line Items]
Property, Plant and Equipment, Useful Life	5 years

PROPERTY AND EQUIPMENT (Detail

PROPERTY AND EQUIPMENT (Details) - Schedule of Property, Plant and Equipment - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 981	$ 439
Less accumulated depreciation	(329)	(150)
Property and equipment, net	652	289
Computer Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	383	234
Furniture and Fixtures [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	88	75
Machinery and Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	286	34
Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	145	96
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 79	$ 0

RIGHT TO USE ASSETS AND LEASE_3

RIGHT TO USE ASSETS AND LEASE LIABILITY (Details)	Aug. 03, 2021USD ($)ft²	Aug. 02, 2021USD ($)ft²	Feb. 10, 2021USD ($)	Feb. 09, 2021USD ($)	Dec. 31, 2021USD ($)	Dec. 31, 2020USD ($)
RIGHT TO USE ASSETS AND LEASE LIABILITY (Details) [Line Items]
Operating Lease, Expense	$ 37,625			$ 16,289	$ 479,746	$ 492,844
Increase (Decrease) in Security Deposits			$ 5,448
Security Deposit			27,404
Operating Lease, Right-of-Use Asset, Amortization Expense	$ 36,756
Operating Lease, Liability		$ 89,629	217,903		656,000	314,000
Area of Real Estate Property (in Square Feet) | ft²	6,590	1,400
Lessee, Operating Lease, Renewal Term		2 years
Operating Lease, Right-of-Use Asset					$ 604,000	$ 306,000
Increase (Decrease) in Operating Lease Liability	$ 868
Number of Leases					5
Building [Member]
RIGHT TO USE ASSETS AND LEASE LIABILITY (Details) [Line Items]
Operating Lease, Expense			63,076
Operating Lease, Right-of-Use Asset, Amortization Expense			60,881
Minimum [Member]
RIGHT TO USE ASSETS AND LEASE LIABILITY (Details) [Line Items]
Operating Lease, Expense	$ 14,828	$ 3,513	$ 13,702
Lessee, Operating Lease, Discount Rate	6.50%
Minimum [Member] | Year Two [Member]
RIGHT TO USE ASSETS AND LEASE LIABILITY (Details) [Line Items]
Operating Lease, Expense		$ 3,618
Maximum [Member]
RIGHT TO USE ASSETS AND LEASE LIABILITY (Details) [Line Items]
Operating Lease, Right-of-Use Asset	$ 492,876
Building [Member]
RIGHT TO USE ASSETS AND LEASE LIABILITY (Details) [Line Items]
Lease Expiration Date					Dec. 31, 2024
Building [Member] | Minimum [Member]
RIGHT TO USE ASSETS AND LEASE LIABILITY (Details) [Line Items]
Operating Lease, Expense					$ 32,143

RIGHT TO USE ASSETS AND LEASE_4

RIGHT TO USE ASSETS AND LEASE LIABILITY (Details) - Right to Use Asset - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Right to Use Asset [Abstract]
Right to use assets, net	$ 803	$ 1,087
Less accumulated depreciation	(199)	(781)
Right to use assets, net	$ 604	$ 306

RIGHT TO USE ASSETS AND LEASE_5

RIGHT TO USE ASSETS AND LEASE LIABILITY (Details) - Lease, Cost - USD ($)	Dec. 31, 2021	Aug. 02, 2021	Feb. 10, 2021	Dec. 31, 2020
Lease, Cost [Abstract]
Lease liability	$ 656,000	$ 89,629	$ 217,903	$ 314,000
Less: short term portion	(283,000)			(313,000)
Long term portion	$ 373,000			$ 1,000

RIGHT TO USE ASSETS AND LEASE_6

RIGHT TO USE ASSETS AND LEASE LIABILITY (Details) - Lessee, Operating Lease, Liability, Maturity - USD ($)	Dec. 31, 2021	Aug. 02, 2021	Feb. 10, 2021	Dec. 31, 2020
Lessee, Operating Lease, Liability, Maturity [Abstract]
Year ended December 31, 2021	$ 304,000
Year ended December 31, 2022	221,000
Year ended December 31, 2024	191,000
Total	716,000
Less: Present value discount	(60,000)
Lease liability	$ 656,000	$ 89,629	$ 217,903	$ 314,000

RIGHT TO USE ASSETS AND LEASE_7

RIGHT TO USE ASSETS AND LEASE LIABILITY (Details) - Lease, Cost - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Lease, Cost [Abstract]
Operating lease expense	$ 441	$ 456
Short-term lease expense	39	35
Variable lease expense	0	2
Lease Cost	$ 480	$ 493

ACCOUNTS PAYABLE AND ACCRUED _3

ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Details) - Schedule of Accounts Payable and Accrued Liabilities - USD ($)	Dec. 31, 2021	Sep. 23, 2021	Dec. 31, 2020
Schedule of Accounts Payable and Accrued Liabilities [Abstract]
Accrued accounting and legal	$ 204,000		$ 177,000
Accrued reimbursements and travel	56,000		56,000
Accrued consulting	264,000		256,000
Accrued research and development expenses	367,000		3,127,000
Accrued product purchases	1,000		30,000
Accrued marketing	38,000		0
Accrued office and other	84,000		127,000
Accrued payroll	552,000		936,000
Accrued settlement related to arbitration	613,000	$ 1,000,000	13,000
	$ 2,179,000		$ 4,722,000

SERIES C 9% CONVERTIBLE PREFE_2

SERIES C 9% CONVERTIBLE PREFERRED STOCK (Details) - USD ($)	Jul. 14, 2020	Jan. 09, 2013	Dec. 31, 2020	Dec. 31, 2021	Dec. 12, 2021	May 20, 2020	Nov. 20, 2019
SERIES C 9% CONVERTIBLE PREFERRED STOCK (Details) [Line Items]
Preferred Stock, Dividend Payment Terms	declared a dividend of one preferred share purchase right for each outstanding share of BioSig’s common stock to stockholders of record on July 27, 2020, and one right will be issued for each new share of common stock issued thereafter.
Preferred Stock, Voting Rights	In the event that a person or group acquires beneficial ownership of 12% or more of BioSig’s then outstanding common stock, subject to certain exceptions, each right would entitle its holder (other than such person or members of such group) to purchase additional shares of BioSig’s common stock having a market value of two times the exercise price of the right. In addition, at any time after a person or group acquires 12% or more of BioSig’s outstanding common stock (unless such person or group acquires 50% or more), the Board may exchange one share of BioSig’s common stock for each outstanding right (other than rights owned by such person or group, which would have become void). The Rights Plan could make it more difficult for a third party to acquire control of BioSig or a large block of our common stock without the approval of our board of directors.
Class of Warrant or Right, Exercise Price of Warrants or Rights			$ 3.75		$ 2.27	$ 10	$ 6.16
Dividends Payable, Current			$ 73,000	$ 82,000
Temporary Equity, Shares Issued			105	105
Temporary Equity, Shares Outstanding			105	105
Series C Preferred Stock [Member]
SERIES C 9% CONVERTIBLE PREFERRED STOCK (Details) [Line Items]
Temporary Equity, Shares Authorized		4,200
Preferred Stock, Dividend Rate, Percentage		9.00%
Temporary Equity, Par Value		$ 1,000
Preferred Stock, Dividend Payment Terms		payable quarterly
Preferred Stock, Convertible, Terms		The holders of the Series C Preferred Stock vote together with the holders of our common stock on an as-converted basis but may not vote the Series C Preferred Stock in excess of the beneficial ownership limitation of the Series C Preferred Stock. The beneficial ownership limitation is 4.99% of our then outstanding shares of common stock following such conversion or exercise, which may be increased to up to 9.99% of our then outstanding shares of common stock following such conversion or exercise upon the request of an individual holder.
Preferred Stock, Voting Rights		The holders of the Series C Preferred Stock vote together with the holders of our common stock on an as-converted basis but may not vote the Series C Preferred Stock in excess of the beneficial ownership limitation of the Series C Preferred Stock. The beneficial ownership limitation is 4.99% of our then outstanding shares of common stock following such conversion or exercise, which may be increased to up to 9.99% of our then outstanding shares of common stock following such conversion or exercise upon the request of an individual holder.
Preferred Stock, Beneficial Ownership Limitation and Covenant, Description		The beneficial ownership limitation is determined on an individual holder basis, such that the as-converted number of shares of one holder is not included in the shares outstanding when calculating the limitation for a different holder.
Conversion of Stock, Shares Issued			44,850
Conversion of Stock, Shares Converted			110
Convertible Preferred Stock Converted to Other Securities			$ 110,000
Dividends Payable, Current			$ 70,341
Temporary Equity, Shares Issued			105
Temporary Equity, Shares Outstanding			105
Dividends Payable			$ 72,517	$ 81,667

STOCKHOLDER EQUITY (Details)

STOCKHOLDER EQUITY (Details) - USD ($)	Aug. 14, 2021	Jul. 02, 2021	Jul. 01, 2021	Apr. 01, 2021	Aug. 28, 2020	Jul. 14, 2020	Jun. 24, 2020	May 20, 2020	Apr. 08, 2020	Mar. 31, 2020	Feb. 25, 2020	Jan. 09, 2013	Feb. 16, 2021	Jan. 31, 2021	Dec. 31, 2020	Mar. 30, 2022	Dec. 31, 2020	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2020
STOCKHOLDER EQUITY (Details) [Line Items]
Preferred Stock, Dividend Payment Terms						declared a dividend of one preferred share purchase right for each outstanding share of BioSig’s common stock to stockholders of record on July 27, 2020, and one right will be issued for each new share of common stock issued thereafter.
Preferred Stock, Par or Stated Value Per Share (in Dollars per share)						$ 0.001									$ 0.001		$ 0.001	$ 0.001	$ 0.001		$ 0.001
Preferred Stock, Redemption Price Per Share (in Dollars per share)						$ 50
Preferred Stock, Voting Rights						In the event that a person or group acquires beneficial ownership of 12% or more of BioSig’s then outstanding common stock, subject to certain exceptions, each right would entitle its holder (other than such person or members of such group) to purchase additional shares of BioSig’s common stock having a market value of two times the exercise price of the right. In addition, at any time after a person or group acquires 12% or more of BioSig’s outstanding common stock (unless such person or group acquires 50% or more), the Board may exchange one share of BioSig’s common stock for each outstanding right (other than rights owned by such person or group, which would have become void). The Rights Plan could make it more difficult for a third party to acquire control of BioSig or a large block of our common stock without the approval of our board of directors.
Preferred Stock, Shares Authorized															1,000,000		1,000,000	1,000,000	1,000,000		1,000,000
Common Stock, Shares Authorized															200,000,000		200,000,000	200,000,000	200,000,000		200,000,000
Common Stock, Par or Stated Value Per Share (in Dollars per share)															$ 0.001		$ 0.001	$ 0.001	$ 0.001		$ 0.001
Common Stock, Shares, Issued															30,764,792		30,764,792	35,567,180	30,764,792		30,764,792
Stock Issued During Period, Shares, Restricted Stock Award, Gross																			219,334
Stock Issued During Period, Shares, New Issues							2,187,500	1,068,550			2,500,000		251,720		83,055		424,357
Proceeds from Issuance of Common Stock (in Dollars)							$ 16,161,980				$ 9,052,331					$ 3,000,000		$ 9,004,000	$ 25,215,000
Payments of Debt Issuance Costs (in Dollars)							$ 1,338,020				$ 947,669
Stock Issued During Period, Shares, Issued for Services														658,868
Stock Issued During Period, Value, Issued for Services (in Dollars)														$ 2,658,224				3,975,000	$ 4,400,000
Class of Warrant or Rights, Exercised																			580,487
Proceeds from Warrant Exercises (in Dollars)																		$ 0	$ 2,090,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period			550,000															9,375	1,203,223
Proceeds from Stock Options Exercised (in Dollars)																		$ 28,000	$ 2,722,000
Stock Issued During Period, Shares, Other			206,250												83,055				83,055
Payments of Stock Issuance Costs (in Dollars)								$ 93,425					$ 40,365				$ 222,397	$ 995,000
At the Market Offering (in Dollars)					$ 45,000,000
Commission Rate																	3.00%
Stock Issued During Period, Value, New Issues (in Dollars)								$ 10,592,075					$ 1,300,135				$ 2,228,000		$ 25,215,000
Stock Repurchased During Period, Shares															80,958
Shares Issued for Services [Member]
STOCKHOLDER EQUITY (Details) [Line Items]
Stock Issued During Period, Shares, Restricted Stock Award, Gross										50,000
Stock Issued During Period, Shares, Issued for Services																		1,124,341	679,555
Stock Issued During Period, Value, Issued for Services (in Dollars)																		$ 3,975,451	$ 4,399,533
Shares Issued, Price Per Share (in Dollars per share)															$ 6.47		$ 6.47		$ 6.47		$ 6.47
Stock in Exchange for Proceeds of Exercise of Warrants [Member]
STOCKHOLDER EQUITY (Details) [Line Items]
Class of Warrant or Rights, Exercised																				542,646
Proceeds from Warrant Exercises (in Dollars)																				$ 2,088,997
Exercise of Options [Member]
STOCKHOLDER EQUITY (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period																		9,375		586,825
Proceeds from Stock Options Exercised (in Dollars)																		$ 27,750		$ 2,722,012
Cashless Exercise of Warrants [Member]
STOCKHOLDER EQUITY (Details) [Line Items]
Class of Warrant or Rights, Exercised																				37,841
Stock Issued During Period, Shares, Other																				12,840
Cashless Exercise of Options [Member]
STOCKHOLDER EQUITY (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period																				616,398
Stock Issued During Period, Shares, Other																				160,743
Underwriting Agreement [Member]
STOCKHOLDER EQUITY (Details) [Line Items]
Stock Issued During Period, Shares, New Issues		2,500,000
Proceeds from Issuance of Common Stock (in Dollars)		$ 9,004,033
Payments of Stock Issuance Costs (in Dollars)		$ 995,966
Restricted Stock Units (RSUs) [Member]
STOCKHOLDER EQUITY (Details) [Line Items]
Stock Issued During Period, Shares, Restricted Stock Award, Gross	50,000
Stock Issued During Period, Shares, Other																		258,084
Viral Clear [Member]
STOCKHOLDER EQUITY (Details) [Line Items]
Stock Issued During Period, Shares, Restricted Stock Award, Gross				40,000
Stock Issued During Period, Shares, New Issues																					1,965,240
Shares Issued, Price Per Share (in Dollars per share)									$ 0.001
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period			550,000															550,000
Stock Issued During Period, Shares, Other			206,250						259,959						80,958				80,958
Stock Issued During Period, Value, New Issues (in Dollars)																					$ 15,600,000
Series E Preferred Stock [Member]
STOCKHOLDER EQUITY (Details) [Line Items]
Preferred Stock, Dividend Payment Terms						Each right will initially trade with common stock, and will allow its holder to purchase from BioSig one one-thousandth of a share of Series F Junior Participating Preferred stock, par value $0.001 per share, for an exercise price of $50.00, once the rights become exercisable.
Preferred Stock, Shares Authorized															1,000		1,000	1,000	1,000		1,000
Series A Preferred Stock [Member]
STOCKHOLDER EQUITY (Details) [Line Items]
Preferred Stock, Shares Authorized															200		200	200	200		200
Series B Preferred Stock [Member]
STOCKHOLDER EQUITY (Details) [Line Items]
Preferred Stock, Shares Authorized															600		600	600	600		600
Series C Preferred Stock [Member]
STOCKHOLDER EQUITY (Details) [Line Items]
Preferred Stock, Dividend Payment Terms												payable quarterly
Preferred Stock, Voting Rights												The holders of the Series C Preferred Stock vote together with the holders of our common stock on an as-converted basis but may not vote the Series C Preferred Stock in excess of the beneficial ownership limitation of the Series C Preferred Stock. The beneficial ownership limitation is 4.99% of our then outstanding shares of common stock following such conversion or exercise, which may be increased to up to 9.99% of our then outstanding shares of common stock following such conversion or exercise upon the request of an individual holder.
Preferred Stock, Shares Authorized															4,200		4,200	4,200	4,200		4,200
Series D Preferred Stock [Member]
STOCKHOLDER EQUITY (Details) [Line Items]
Preferred Stock, Shares Authorized															1,400		1,400	1,400	1,400		1,400
Series F Preferred Stock [Member]
STOCKHOLDER EQUITY (Details) [Line Items]
Preferred Stock, Shares Authorized															200,000		200,000	200,000	200,000		200,000
Viral Clear [Member]
STOCKHOLDER EQUITY (Details) [Line Items]
Stock Issued During Period, Shares, New Issues								1,068,550
Shares Issued, Price Per Share (in Dollars per share)								$ 10
Stock Issued During Period, Value, New Issues (in Dollars)								$ 10,592,075
Common Stock, Conversion Basis								each share of ViralClear common stock may be exchanged into 0.9 of a share our common stock if the ViralClear common stock subject to the share exchange was purchased in the August or September 2019 private placements, or 1.1 shares of our common stock if the ViralClear common

OPTIONS, RESTRICTED STOCK UNI_3

OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details)

Mar. 30, 2022

Dec. 28, 2021$ / sharesshares

Dec. 15, 2021$ / sharesshares

Oct. 21, 2021$ / sharesshares

Oct. 04, 2021$ / sharesshares

Sep. 17, 2021$ / sharesshares

Aug. 31, 2021$ / sharesshares

Aug. 14, 2021shares

Aug. 03, 2021$ / sharesshares

Jul. 07, 2021$ / sharesshares

Jul. 01, 2021shares

Jun. 30, 2021USD ($)shares

Jun. 28, 2021USD ($)shares

Jun. 01, 2021USD ($)shares

May 18, 2021$ / sharesshares

Apr. 13, 2021$ / sharesshares

Apr. 09, 2021$ / sharesshares

Apr. 01, 2021shares

Mar. 08, 2021shares

Feb. 16, 2021$ / sharesshares

Jan. 21, 2021$ / sharesshares

Jan. 05, 2021shares

Jan. 04, 2021shares

Oct. 09, 2020$ / sharesshares

Aug. 26, 2020$ / sharesshares

Jul. 13, 2020shares

May 20, 2020$ / sharesshares

Apr. 14, 2020$ / sharesshares

Apr. 08, 2020shares

Mar. 31, 2020$ / sharesshares

Mar. 30, 2020shares

Mar. 25, 2020shares

Mar. 24, 2020$ / sharesshares

Feb. 25, 2020$ / sharesshares

Jan. 10, 2020

Sep. 24, 2019shares

Mar. 14, 2019shares

May 04, 2018$ / sharesshares

Nov. 24, 2017

Jun. 20, 2017shares

Oct. 19, 2012shares

Jan. 31, 2021shares

Dec. 31, 2020$ / sharesshares

Dec. 31, 2021USD ($)$ / sharesshares

Dec. 31, 2020USD ($)$ / sharesshares

Dec. 12, 2021$ / shares

Nov. 20, 2019$ / shares

OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Terms of Award

the exercise price of an Incentive Stock Option should not be less than 110% of fair market value of the common stock at the date of the grant for a 10% or more stockholder and 100% of fair market value for a grantee who is not 10% stockholder

Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant

2,330,750

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross

1,818,000

1,120,000

Stock Issued During Period, Shares, Issued for Services

658,868

Share Price (in Dollars per share) | $ / shares

$ 2.23

Share-based Compensation Arrangement by Share-basd Payment Award, Options, Exercise Price (in Dollars per share) | $ / shares

$ 2.44

$ 2.58

$ 2.89

$ 2.99

$ 2.98

$ 3.61

$ 3.2

$ 4.42

$ 4.38

$ 4.97

$ 4.23

$ 5.03

$ 10.49

$ 4.66

Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period

10 years

10 years

10 years

10 years

10 years

10 years

10 years

10 years

10 years

10 years

10 years

10 years

10 years

10 years

10 years

10 years

Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights

one-third vesting on the first anniversary of the date of grant, and the remaining two-thirds vesting in substantially equal quarterly installments over the following two years

one-third vesting on the first anniversary of the date of grant, and the remaining two-thirds vesting in substantially equal quarterly installments over the following two years

with half immediate vesting and half vesting on September 20, 2022

one-third vesting on the first anniversary of the date of grant, and the remaining two-thirds vesting in substantially equal quarterly installments over the following two years

one-third vesting on the first anniversary of the date of grant, and the remaining two-thirds vesting in substantially equal quarterly installments over the following two years

one-third vesting on the one-year anniversary and two-thirds vesting quarterly thereafter beginning May 18, 2022 for two years

one-third vesting on the one-year anniversary and two-thirds vesting quarterly thereafter beginning April 13, 2022 for two years

one-third vesting on the one-year anniversary and two-thirds vesting quarterly thereafter beginning April 9, 2022 for two years

one-third vesting on the one year anniversary and two-thirds vesting quarterly thereafter beginning February 16, 2022 for two years

one-third vesting on the one-year anniversary and two-thirds vesting quarterly thereafter beginning January 12, 2022 for two years

one-third vesting on the one year anniversary and two-thirds vesting quarterly thereafter beginning January 9, 2022 for two years.

one-third vesting on the one year anniversary and two-thirds vesting quarterly thereafter beginning November 26, 2021 for two years

one

40,000 fully vested and exercisable at the date of grant and 25,000 options vesting quarterly over three years

320,000 vesting immediately, and 640,000 vesting upon ViralClear meeting certain milestones

25,000 vesting immediately and 75,000 quarterly vesting beginning June 30, 2020 for two years

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures

425,000

351,000

50,000

50,000

40,000

47,500

75,000

150,000

25,000

90,000

102,000

387,500

105,000

625,000

Stock Issued During Period, Shares, Restricted Stock Award, Gross

219,334

Class of Warrant or Rights, Granted

6,575

125,000

125,000

Number of Employees

2

2

3

3

3

Options Modified

221,240

145,000

APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition (in Dollars) | $

$ 111,402

$ 182,514

Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share) | $ / shares

$ 10

$ 3.75

$ 3.75

$ 2.27

$ 6.16

Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Granted

82,716

960,000

338,000

Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period

50,000

30,000

Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value (in Dollars) | $

$ 232,375

$ 109,725

Share-based Payment Arrangement, Noncash Expense (in Dollars) | $

$ 0

$ 1,299,000

Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in Dollars per share) | $ / shares

$ 2.44

$ 2.89

$ 3.69

$ 4.98

Stock Issued During Period, Shares, Other

206,250

83,055

83,055

Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period

550,000

9,375

1,203,223

Services Provided [Member]

OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) [Line Items]

Share-based Compensation Arrangement by Share-basd Payment Award, Options, Exercise Price (in Dollars per share) | $ / shares

$ 2.44

Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period

10 years

Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights

25,000 options vested immediately and 50,000 options vesting on the one-year anniversary

On March 24, 2020, BioSig Technologies, Inc. granted 100,000 options to purchase the company stock in connection with the services rendered at the exercise price of $2.96 per share for a term of ten years with 25,000 vesting immediately and 75,000 quarterly vesting beginning June 30, 2020 for two

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures

75,000

25,000

Number of Employees

3

Shares Issued for Services [Member]

OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period

3 years

Stock Issued During Period, Shares, Issued for Services

1,124,341

679,555

Share-based Compensation Arrangement by Share-basd Payment Award, Options, Exercise Price (in Dollars per share) | $ / shares

$ 3.73

Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period

10 years

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures

50,000

Stock Issued During Period, Shares, Restricted Stock Award, Gross

50,000

Viral Clear [Member]

OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross

1,599,173

Stock Issued During Period, Shares, Restricted Stock Award, Gross

40,000

Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in Dollars per share) | $ / shares

$ 5.31

Stock Issued During Period, Shares, Other

206,250

259,959

80,958

80,958

Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period

550,000

550,000

Employees [Member]

OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period

3 years

Share-based Compensation Arrangement by Share-basd Payment Award, Options, Exercise Price (in Dollars per share) | $ / shares

$ 4.66

Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period

10 years

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures

90,000

Director [Member]

OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross

746,507

Options Modified

25,000

125,000

APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition (in Dollars) | $

$ 26,577

Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Granted

329,000

Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period

50,000

Share-based Payment Arrangement, Option [Member] | Viral Clear [Member]

OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period

10 years

Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights

1,278,999 vested immediately, 120,174 quarterly over one year and 200,000 quarterly over two years

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures

1,599,173

Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount (in Dollars) | $

$ 182,604

Share-based Payment Arrangement, Noncash Expense (in Dollars) | $

$ 146,083

$ 5,873,376

Share-based Payment Arrangement, Option [Member] | Director [Member]

OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) [Line Items]

Options Modified

240,000

Restricted Stock Units (RSUs) [Member]

OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights

vesting quarterly for one year

105,000 vesting one-third on the one-year anniversary and two-thirds vesting quarterly thereafter beginning January 4, 2022 for two years and with 115,000 vesting quarterly for one year

Stock Issued During Period, Shares, Restricted Stock Award, Gross

50,000

Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Granted

31,000

220,000

301,000

175,000

Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period

258,084

219,334

Share-based Payment Arrangement, Noncash Expense (in Dollars) | $

$ 950,281

$ 1,151,676

Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount (in Dollars) | $

$ 286,417

Stock Issued During Period, Shares, Other

258,084

Restricted Stock Units (RSUs) [Member] | Viral Clear [Member]

OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) [Line Items]

Share-based Payment Arrangement, Noncash Expense (in Dollars) | $

$ 904,112

$ 5,893,320

Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount (in Dollars) | $

$ 186,047

Warrants at $3.75 [Member]

OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) [Line Items]

Class of Warrant or Rights, Granted

65,000

Warrants at $4.80 [Member]

OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) [Line Items]

Class of Warrant or Rights, Granted

125,000

125,000

Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share) | $ / shares

$ 4.8

$ 4.8

$ 4.8

Warrant, Expriation Date

Feb. 21, 2025

Share-based Payment Arrangement, Tranche One [Member] | Services Provided [Member]

OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) [Line Items]

Share-based Compensation Arrangement by Share-basd Payment Award, Options, Exercise Price (in Dollars per share) | $ / shares

$ 7.57

Maximum [Member]

OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period

3 years

Maximum [Member] | Share-based Payment Arrangement, Option [Member] | Viral Clear [Member]

OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) [Line Items]

Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in Dollars per share) | $ / shares

$ 10

Minimum [Member] | Share-based Payment Arrangement, Option [Member] | Viral Clear [Member]

OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) [Line Items]

Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in Dollars per share) | $ / shares

$ 5

Minimum [Member] | Restricted Stock Units (RSUs) [Member]

OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period

1 year

2012 Equity Incentive Plan [Member] | Officers, Directors and Key Consultants [Member]

OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross

1,818,000

1,070,000

Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period

50,000

Stock Issued During Period, Shares, Issued for Services

1,185,872

634,517

2012 Equity Incentive Plan [Member] | Share-based Payment Arrangement, Option [Member]

OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized

14,474,450

Share-based Compensation Arrangement by Share-based Payment Award, Terms of Award

the exercise price of an Incentive Stock Option should not be less than 110% of fair value of the common stock at the date of the grant for a 10% or more stockholder and 100% of fair value for a grantee who is not 10% stockholder

Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period

3 years

Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant

3,048,522

Share Price (in Dollars per share) | $ / shares

$ 2.23

$ 2.23

Share-based Compensation Arrangement by Share-basd Payment Award, Options, Exercise Price (in Dollars per share) | $ / shares

$ 2.96

Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period

10 years

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures

100,000

Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value (in Dollars) | $

$ 3,357,274

$ 5,217,761

Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount (in Dollars) | $

$ 3,655,519

2012 Equity Incentive Plan [Member] | Maximum [Member] | Share-based Payment Arrangement, Option [Member]

OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period

10 years

Warrants at $4.43 [Member] | 2012 Equity Incentive Plan [Member] | Share-based Payment Arrangement, Option [Member]

OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross

60,000

Share-based Compensation Arrangement by Share-basd Payment Award, Options, Exercise Price (in Dollars per share) | $ / shares

$ 6

Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period

10 years

Options at $5.66 [Member] | 2012 Equity Incentive Plan [Member] | Share-based Payment Arrangement, Option [Member] | Services Provided [Member]

OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross

4,000,000

OPTIONS, RESTRICTED STOCK UNI_4

OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) - Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range - $ / shares	Jan. 01, 2020	Dec. 31, 2021	Dec. 31, 2020
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Options Outstanding, Number of Options	3,980,804	4,568,484	3,568,497
Options Outstanding, Weighted Average Remaining Life	6 years 3 months 18 days	6 years 10 months 24 days	7 years
Options Exercisable, Number of Options		3,071,810
Under $3.00 [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Options Outstanding, Exercise Price, Lower Range Limit (in Dollars per share)		$ 3
Options Outstanding, Exercise Price, Upper Range Limit (in Dollars per share)		$ 3
Options Outstanding, Number of Options		1,035,375
Options Outstanding, Weighted Average Remaining Life		9 years 6 months
Options Exercisable, Number of Options		560,000
Options $3.00 - $3.99 [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Options Outstanding, Exercise Price, Lower Range Limit (in Dollars per share)		$ 3
Options Outstanding, Exercise Price, Upper Range Limit (in Dollars per share)		$ 3.99
Options Outstanding, Number of Options		587,466
Options Outstanding, Weighted Average Remaining Life		6 years 6 months
Options Exercisable, Number of Options		387,466
Options $4.00 to $4.99 [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Options Outstanding, Exercise Price, Lower Range Limit (in Dollars per share)		$ 4
Options Outstanding, Exercise Price, Upper Range Limit (in Dollars per share)		$ 4.99
Options Outstanding, Number of Options		1,762,916
Options Outstanding, Weighted Average Remaining Life		6 years 2 months 12 days
Options Exercisable, Number of Options		1,151,545
Options $5.00 to $5.99 [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Options Outstanding, Exercise Price, Lower Range Limit (in Dollars per share)		$ 5
Options Outstanding, Exercise Price, Upper Range Limit (in Dollars per share)		$ 5.99
Options Outstanding, Number of Options		156,132
Options Outstanding, Weighted Average Remaining Life		7 years 1 month 6 days
Options Exercisable, Number of Options		119,464
Options $6.00 to $6.99 [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Options Outstanding, Exercise Price, Lower Range Limit (in Dollars per share)		$ 6
Options Outstanding, Exercise Price, Upper Range Limit (in Dollars per share)		$ 6.99
Options Outstanding, Number of Options		591,542
Options Outstanding, Weighted Average Remaining Life		5 years
Options Exercisable, Number of Options		478,846
Options $7.00 to $7.99 [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Options Outstanding, Exercise Price, Lower Range Limit (in Dollars per share)		$ 7
Options Outstanding, Exercise Price, Upper Range Limit (in Dollars per share)		$ 7.99
Options Outstanding, Number of Options		191,720
Options Outstanding, Weighted Average Remaining Life		6 years 10 months 24 days
Options Exercisable, Number of Options		177,138
Options over $8.00 [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Options Outstanding, Exercise Price, Lower Range Limit (in Dollars per share)		$ 8
Options Outstanding, Exercise Price, Upper Range Limit (in Dollars per share)		$ 8
Options Outstanding, Number of Options		243,333
Options Outstanding, Weighted Average Remaining Life		6 years 3 months 18 days
Options Exercisable, Number of Options		197,351
Options at $5.00 [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Options Outstanding, Exercise Price, Lower Range Limit (in Dollars per share)		$ 5
Options Outstanding, Exercise Price, Upper Range Limit (in Dollars per share)		$ 5
Options Outstanding, Number of Options		125,000
Options Outstanding, Weighted Average Remaining Life		7 years 2 months 12 days
Options Exercisable, Number of Options		83,331

OPTIONS, RESTRICTED STOCK UNI_5

OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) - Schedule of Share-based Compensation, Stock Options, Activity - $ / shares	Dec. 28, 2021	Oct. 04, 2021	Jul. 01, 2021	Jan. 01, 2020	Dec. 31, 2021	Dec. 31, 2020
Schedule of Share-based Compensation, Stock Options, Activity [Abstract]
Outstanding, Shares (in Shares)				3,980,804	4,568,484	3,568,497
Options Outstanding, Weighted-Average Exercise Price				$ 5.58	$ 4.57	$ 5.59
Options Outstanding, Weighted-Average Remaining Contractual Term				6 years 3 months 18 days	6 years 10 months 24 days	7 years
Options Outstanding, Aggregate Intrinsic Value				$ 3,130,791		$ 110,961
Options Exercisable, Shares (in Shares)					3,071,810
Options Exercisable, Weighted-Average Exercise Price					$ 4.83
Options Exercisable, Weighted-Average Remaining Contractual Term					6 years
Options Granted, Shares (in Shares)					1,818,000	1,120,000
Options Granted, Weighted-Average Exercise Price	$ 2.44	$ 2.89			$ 3.69	$ 4.98
Options Granted, Weighted-Average Remaining Contractual Term					10 years	10 years
Options Exercised, Shares (in Shares)			(550,000)		(9,375)	(1,203,223)
Options Exercised, Weighted-Average Exercise Price					$ 2.96	$ 5.08
Options Canceled, Shares (in Shares)					(808,638)	(329,084)
Options Canceled, Weighted-Average Exercise Price					$ 6.19	$ 5.19

OPTIONS, RESTRICTED STOCK UNI_6

OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) - Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions - Share-based Payment Arrangement, Option [Member] - $ / shares	Jun. 30, 2021	Jun. 28, 2021	Dec. 31, 2021	Dec. 31, 2020
Minimum [Member]
OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) - Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Line Items]
Risk-free interest rate			0.77%	0.42%
Dividend yield	0.00%	0.00%	0.00%	0.00%
Stock price volatility	88.59%	88.57%	82.50%	86.51%
Expected life	1 year 3 months	3 months	5 years	5 years
Weighted average grant date fair value (in Dollars per share)			$ 2.55	$ 4.03
Minimum [Member] | Viral Clear [Member]
OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) - Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Line Items]
Dividend yield	0.00%			0.00%
Stock price volatility	88.59%			125.16%
Expected life	7 months 2 days			5 years
Weighted average grant date fair value (in Dollars per share)				$ 4.51
Maximum [Member]
OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) - Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Line Items]
Risk-free interest rate			1.49%	1.83%
Dividend yield		0.00%	0.00%	0.00%
Stock price volatility		88.57%	95.98%	93.43%
Expected life	3 years	2 years	10 years	10 years
Weighted average grant date fair value (in Dollars per share)			$ 2.55	$ 4.03
Maximum [Member] | Viral Clear [Member]
OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) - Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Line Items]
Dividend yield	0.00%			0.00%
Stock price volatility	88.59%			126.03%
Expected life	3 years			6 years
Weighted average grant date fair value (in Dollars per share)				$ 4.51

OPTIONS, RESTRICTED STOCK UNI_7

OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) - Schedule of Warrants or Rights, Shares Authorized, by Exercise Price Range - $ / shares	12 Months Ended
	Dec. 31, 2021	Dec. 12, 2021	Jul. 07, 2021	Dec. 31, 2020	May 20, 2020	Feb. 25, 2020	Dec. 31, 2019	Nov. 20, 2019
OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) - Schedule of Warrants or Rights, Shares Authorized, by Exercise Price Range [Line Items]
Exercise Price, Warrants (in Dollars per share)		$ 2.27		$ 3.75	$ 10			$ 6.16
Number of Warrants Outstanding	818,910			1,446,200			2,744,718
Warrants at $4.80 [Member]
OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) - Schedule of Warrants or Rights, Shares Authorized, by Exercise Price Range [Line Items]
Exercise Price, Warrants (in Dollars per share)	$ 4.8		$ 4.8			$ 4.8
Number of Warrants Outstanding	250,000
Expiration Date, Warrants	February 2025 to July 2026
Warrants at $6.16 [Member]
OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) - Schedule of Warrants or Rights, Shares Authorized, by Exercise Price Range [Line Items]
Exercise Price, Warrants (in Dollars per share)	$ 6.16							$ 6.16
Number of Warrants Outstanding	568,910
Expiration Date, Warrants	November 2027

OPTIONS, RESTRICTED STOCK UNI_8

OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) - Schedule of Stockholders' Equity Note, Warrants or Rights - USD ($)	May 20, 2020	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Schedule of Stockholders' Equity Note, Warrants or Rights [Abstract]
Warrants Outstanding, Shares		818,910	1,446,200	2,744,718
Warrants Outstanding, Weighted-Average Exercise Price		$ 5.74	$ 5.44	$ 5.4
Warrants Outstanding, Weighted-Average Remaining Contractual Term		5 years 3 months 18 days	3 years 3 months 18 days	2 years 2 months 12 days
Warrants Outstanding, Aggregate Intrinsic Value			$ 1,500	$ 3,410,763
Warrants Vested and expected to vest, Shares		818,910
Warrants Vested and expected to vest, Weighted-Average Exercise Price		$ 5.74
Warrants Vested and expected to vest, Weighted-Average Remaining Contractual Term		5 years 3 months 18 days
Warrants Exercisable, Shares		818,910
Warrants Exercisable, Weighted-Average Exercise Price		$ 5.74
Warrants Exercisable, Weighted-Average Remaining Contractual Term		5 years 3 months 18 days
Warrants Granted, Shares	6,575	125,000	125,000
Warrants Granted, Weighted-Average Exercise Price		$ 4.8	$ 4.8
Warrants Granted, Weighted-Average Remaining Contractual Term		5 years	4 years 2 months 12 days
Warrants Exercised, Shares			(580,487)
Warrants Exercised, Weighted-Average Exercise Price			$ 3.89
Warrants Canceled, Shares		(752,290)	(843,031)
Warrants Canceled, Weighted-Average Exercise Price		$ 5	$ 6.29

OPTIONS, RESTRICTED STOCK UNI_9

OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) - Nonvested Restricted Stock Shares Activity - shares	Jun. 30, 2021	Jun. 01, 2021	Mar. 08, 2021	Jan. 04, 2021	Jul. 13, 2020	Mar. 30, 2020	Mar. 25, 2020	Dec. 31, 2021	Dec. 31, 2020
OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) - Nonvested Restricted Stock Shares Activity [Line Items]
Restricted shares Granted					(82,716)	(960,000)	(338,000)
Restricted shares Granted					82,716	960,000	338,000
Restricted shares Vested	(50,000)	(30,000)
Restricted shares issued								1,318,679
Restricted Stock Units (RSUs) [Member]
OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) - Nonvested Restricted Stock Shares Activity [Line Items]
Restricted shares issued								218,334	262,668
Restricted shares Granted			(31,000)	(220,000)				(301,000)	(175,000)
Restricted shares Granted			31,000	220,000				301,000	175,000
Restricted shares Vested								(258,084)	(219,334)
Forfeited								(120,000)
Vested restricted shares								0
Unvested restricted shares								141,250
Restricted shares issued									218,334
Restricted Stock [Member]
OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) - Nonvested Restricted Stock Shares Activity [Line Items]
Restricted shares issued								1,420,716	40,000
Restricted shares Granted								(40,000)	(1,380,716)
Restricted shares Granted								40,000	1,380,716
Forfeited								(62,037)
Vested restricted shares								678,679
Unvested restricted shares								640,000
Restricted shares issued									1,420,716

OPTIONS, RESTRICTED STOCK UN_10

OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) - Share-based Payment Arrangement, Option, Activity - Viral Clear [Member] - $ / shares	Jul. 01, 2021	Jan. 01, 2020	Dec. 31, 2021	Dec. 31, 2020
OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) - Share-based Payment Arrangement, Option, Activity [Line Items]
Options Outstanding, Shares		575,000	1,527,666	575,000
Options Outstanding, Weighted-Average Exercise Price		$ 5	$ 5	$ 5
Options Outstanding, Weighted-Average Remaining Contractual Term		9 years 3 months 18 days	7 years 2 months 12 days	4 years
Exercisable at December 31, 2020			83,331
Exercisable at December 31, 2020			$ 5
Exercisable at December 31, 2020			6 years 7 months 6 days
Exercised, Shares	(550,000)		(550,000)
Exercised			$ 5
Grants, Shares				1,599,173
Grants, Weighted-Average Exercise Price				$ 5.31
Grants, Weighted-Average Remaining Contractual Term				9 years 7 months 6 days
Forfeited/expired, Shares			(852,666)	(646,507)
Forfeited/expired, Weighted-Average Exercise Price			$ 5	$ 5.77
Options Outstanding, Shares			125,000	1,527,666
Options Outstanding, Weighted-Average Exercise Price			$ 5	$ 5

OPTIONS, RESTRICTED STOCK UN_11

OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) - Schedule of Warrants or Rights, Shares Authorized, Exercise Price Range - Viral Clear [Member]	12 Months Ended
	Dec. 31, 2020$ / sharesshares
OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) - Schedule of Warrants or Rights, Shares Authorized, Exercise Price Range [Line Items]
Number Outstanding	480,347
Warrants at $5.00 [Member]
OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) - Schedule of Warrants or Rights, Shares Authorized, Exercise Price Range [Line Items]
Exercise Price (in Dollars per share) | $ / shares	$ 5
Number Outstanding	473,772
Expiration Date	November 2027
Warrants $10.00 [Member]
OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) - Schedule of Warrants or Rights, Shares Authorized, Exercise Price Range [Line Items]
Exercise Price (in Dollars per share) | $ / shares	$ 10
Number Outstanding	6,575
Expiration Date	May 2025

NON-CONTROLLING INTEREST (Detai

NON-CONTROLLING INTEREST (Details) - USD ($)	Jul. 01, 2021	Apr. 01, 2021	Jun. 24, 2020	May 20, 2020	Apr. 08, 2020	Mar. 24, 2020	Feb. 25, 2020	Feb. 16, 2021	Dec. 31, 2020	Dec. 31, 2020	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2020
NON-CONTROLLING INTEREST (Details) [Line Items]
Stock Issued During Period, Shares, Other	206,250								83,055			83,055
Stock Issued During Period, Shares, New Issues			2,187,500	1,068,550			2,500,000	251,720	83,055	424,357
Stock Issued During Period, Value, New Issues (in Dollars)				$ 10,592,075				$ 1,300,135		$ 2,228,000		$ 25,215,000
Payments of Stock Issuance Costs (in Dollars)				$ 93,425				$ 40,365		$ 222,397	$ 995,000
Stock Issued During Period, Shares, Restricted Stock Award, Gross												219,334
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period	550,000										9,375	1,203,223
Viral Clear [Member]
NON-CONTROLLING INTEREST (Details) [Line Items]
Equity Method Investment, Ownership Percentage									68.40%	68.40%		68.40%	68.40%
Viral Clear [Member]
NON-CONTROLLING INTEREST (Details) [Line Items]
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares						634,910
Business Acquisition, Equity Interest Issued or Issuable, Value Assigned (in Dollars)						$ 3,174,550
Stock Issued During Period, Shares, Other	206,250				259,959				80,958			80,958
Shares Issued, Price Per Share (in Dollars per share)					$ 0.001
Stock Issued During Period, Shares, New Issues													1,965,240
Stock Issued During Period, Value, New Issues (in Dollars)													$ 15,600,000
Stock Issued During Period, Shares, Restricted Stock Award, Gross		40,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period	550,000										550,000
Equity Method Investment, Ownership Percentage									68.44%	68.44%		68.44%	68.44%
Viral Clear [Member]
NON-CONTROLLING INTEREST (Details) [Line Items]
Payments to Acquire Productive Assets (in Dollars)						$ 350,000

NON-CONTROLLING INTEREST (Det_2

NON-CONTROLLING INTEREST (Details) - Schedule of Non-Controlling Interest - Viral Clear [Member] - Viral Clear [Member] - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
NON-CONTROLLING INTEREST (Details) - Schedule of Non-Controlling Interest [Line Items]
Net loss		$ (28,372)	$ (3,077)
Average Non-controlling interest percentage of profit/losses	24.40%	30.44%
Net loss attributable to the non-controlling interest	$ (6,922)	$ (939)

NON-CONTROLLING INTEREST (Det_3

NON-CONTROLLING INTEREST (Details) - Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Abstract]
Balance	$ 802	$ 515
Allocation of equity to non-controlling interest due to equity-based compensation issued	348	2,782
Allocation of equity to non-controlling interest to due change in fair value of modified option	8
Allocation of equity to non-controlling interest due to sale of subsidiary stock		3,468
Allocation of equity to non-controlling interest due to issuance of equity to acquire Trek and research and development		983
Allocation of equity from non-controlling interest due to parent reacquiring shares shareholders		(24)
Net loss attributable to non-controlling interest	(939)	(6,922)
Balance	$ 219	$ 802

COMMITMENTS AND CONTINGENCIES (

COMMITMENTS AND CONTINGENCIES (Details) - USD ($)	Sep. 23, 2021	Jan. 08, 2021	May 20, 2020	Nov. 20, 2019	Mar. 15, 2017	Jun. 30, 2021	Dec. 31, 2021	Dec. 31, 2020	Dec. 12, 2021
COMMITMENTS AND CONTINGENCIES (Details) [Line Items]
Agreement Term					10 years
Royalty Percentage of Net Sales				10.00%
Warrants and Rights Outstanding, Term				8 years
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)			$ 10	$ 6.16				$ 3.75	$ 2.27
Other Commitment				$ 50,000
Royalty Guarantees, Commitments, Amount				$ 700,000
Payments for Royalties						$ 75,000
Class of Warrant or Rights, Granted (in Shares)			6,575				125,000	125,000
Defined Contribution Plan, Cost							$ 252,452	$ 170,317
Long-term Purchase Commitment, Amount							1,443,398
Loss Contingency, Damages Sought, Value		$ 1,530,000
Settlement Liabilities, Current	$ 1,000,000						613,000	$ 13,000
Gain (Loss) Related to Litigation Settlement							$ 553,000
Payment Due September 30, 2021 [Member]
COMMITMENTS AND CONTINGENCIES (Details) [Line Items]
Payments for Legal Settlements	400,000
Payment Due December 31, 2021 [Member]
COMMITMENTS AND CONTINGENCIES (Details) [Line Items]
Payments for Legal Settlements	300,000
Payment Due March 31, 2022 [Member]
COMMITMENTS AND CONTINGENCIES (Details) [Line Items]
Payments for Legal Settlements	$ 300,000
Warrants at $6.16 [Member]
COMMITMENTS AND CONTINGENCIES (Details) [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)				$ 6.16			$ 6.16
Warrants at $5.00 [Member]
COMMITMENTS AND CONTINGENCIES (Details) [Line Items]
Warrants and Rights Outstanding, Term						8 years
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)				$ 5
Class of Warrant or Rights, Granted (in Shares)				473,772
Minimum [Member]
COMMITMENTS AND CONTINGENCIES (Details) [Line Items]
Royalty Percentage of Net Sales					1.00%
Minimum [Member] | Employee Agreement [Member] | Chief Executive Officer [Member]
COMMITMENTS AND CONTINGENCIES (Details) [Line Items]
Royalty Guarantees, Commitments, Amount				$ 625,000
Minimum [Member] | Employee Agreement [Member] | Chief Executive Officer [Member] | Annual Salary [Member]
COMMITMENTS AND CONTINGENCIES (Details) [Line Items]
Other Commitment				25,000
Maximum [Member]
COMMITMENTS AND CONTINGENCIES (Details) [Line Items]
Royalty Percentage of Net Sales					2.00%
Tools Agreement [Member]
COMMITMENTS AND CONTINGENCIES (Details) [Line Items]
Other Commitment				100,000
Royalty Guarantees, Commitments, Amount				$ 550,000
Payments for Royalties						$ 75,000

SEGMENT REPORTING (Details) - S

SEGMENT REPORTING (Details) - Schedule of Segment Reporting Information, by Segment - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Segment Reporting Information [Line Items]
Revenues (from external customers)	$ 441	$ 0
Operating Expenses	33,653	59,184
Income (loss) from operations	(32,856)	(59,140)
Total Assets	15,519	30,386
Corporate Segment [Member]
Segment Reporting Information [Line Items]
Revenues (from external customers)	441	0
Operating Expenses	30,016	30,756
Income (loss) from operations	(29,772)	(30,727)
Total Assets	13,595	24,764
Viral Clear [Member]
Segment Reporting Information [Line Items]
Revenues (from external customers)	0	0
Operating Expenses	3,630	28,387
Income (loss) from operations	(3,077)	(28,372)
Total Assets	1,924	5,622
NeuroClear Technologies, Inc ("NeuroClear") [Member]
Segment Reporting Information [Line Items]
Revenues (from external customers)	0	0
Operating Expenses	7	41
Income (loss) from operations	(7)	(41)
Total Assets	$ 0	$ 0

RELATED PARTY TRANSACTIONS (Det

RELATED PARTY TRANSACTIONS (Details) - USD ($)

Dec. 28, 2021

Dec. 15, 2021

Oct. 21, 2021

Oct. 04, 2021

Sep. 17, 2021

Aug. 31, 2021

Aug. 03, 2021

Jul. 01, 2021

Jun. 30, 2021

Jun. 28, 2021

Jun. 01, 2021

May 18, 2021

Apr. 13, 2021

Apr. 09, 2021

Feb. 16, 2021

Jan. 21, 2021

Jan. 05, 2021

Oct. 09, 2020

Aug. 12, 2020

Jul. 13, 2020

May 20, 2020

Apr. 14, 2020

Mar. 30, 2020

Mar. 25, 2020

Sep. 24, 2019

Dec. 31, 2021

Dec. 31, 2020

Dec. 31, 2019

RELATED PARTY TRANSACTIONS (Details) [Line Items]

Due to Related Parties, Current (in Dollars)

$ 86,208

$ 317,000

Related Party Transaction, Description of Transaction

ViralClear agreed to pay Weild & Co a 5% cash and a 5% warrant or other securities of the aggregate subscriptions placed by Weild & Co. No costs have been incurred as of the date of this filing

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross

1,818,000

1,120,000

Shares Issued, Shares, Share-based Payment Arrangement, before Forfeiture

450,000

Stock Issued During Period, Shares, Restricted Stock Award, Gross

219,334

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures

425,000

351,000

50,000

50,000

40,000

47,500

75,000

150,000

25,000

90,000

102,000

387,500

105,000

625,000

Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period

550,000

9,375

1,203,223

Options Modified

221,240

145,000

Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Granted

82,716

960,000

338,000

Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period

50,000

30,000

Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in Dollars per share)

$ 2.44

$ 2.89

$ 3.69

$ 4.98

Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period

10 years

10 years

10 years

10 years

10 years

10 years

10 years

10 years

10 years

10 years

10 years

10 years

10 years

10 years

10 years

10 years

Cashless Exercise of Options [Member]

RELATED PARTY TRANSACTIONS (Details) [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period

616,398

Director #6 [Member]

RELATED PARTY TRANSACTIONS (Details) [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross

1,138,000

Director [Member]

RELATED PARTY TRANSACTIONS (Details) [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross

746,507

Options Modified

25,000

125,000

Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Granted

329,000

Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period

50,000

Director [Member] | Share-based Payment Arrangement, Option [Member]

RELATED PARTY TRANSACTIONS (Details) [Line Items]

Options Modified

240,000

Officer [Member]

RELATED PARTY TRANSACTIONS (Details) [Line Items]

Shares Issued, Shares, Share-based Payment Arrangement, before Forfeiture

175,000

Stock Issued During Period, Shares, Restricted Stock Award, Gross

100,000

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures

675,000

Director #4 [Member] | Cashless Exercise of Options [Member]

RELATED PARTY TRANSACTIONS (Details) [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period

4,030

Director #2 [Member]

RELATED PARTY TRANSACTIONS (Details) [Line Items]

Options Modified

50,000

Viral Clear [Member] | Director [Member]

RELATED PARTY TRANSACTIONS (Details) [Line Items]

Options Modified

25,000

Options at $3.73 [Member]

RELATED PARTY TRANSACTIONS (Details) [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period

50,000

Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price (in Dollars per share)

$ 3.73

Options at $7.10 [Member]

RELATED PARTY TRANSACTIONS (Details) [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period

50,000

Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price (in Dollars per share)

$ 7.1

INCOME TAXES (Details)

INCOME TAXES (Details) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Income Tax Disclosure [Abstract]
Operating Loss Carryforwards	$ 116,000,000
Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount	(6,470,000)
Deferred Tax Assets, Valuation Allowance	$ 31,170,000	$ 24,700,000
Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate	(21.00%)	21.00%
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent		21.00%

INCOME TAXES (Details) - Schedu

INCOME TAXES (Details) - Schedule of Effective Income Tax Rate Reconciliation	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Schedule of Effective Income Tax Rate Reconciliation [Abstract]
Statutory rate on pre-tax book loss	21.00%	(21.00%)
Stock based compensation	0.00%	8.10%
Fair value of warrant to acquire research and development	0.00%	1.59%
Other	(1.30%)	0.03%
Valuation allowance	(19.70%)	11.28%
	0.00%	0.00%

INCOME TAXES (Details) - Sche_2

INCOME TAXES (Details) - Schedule of Deferred Tax Assets and Liabilities - USD ($)	Dec. 31, 2021	Dec. 31, 2020
Schedule of Deferred Tax Assets and Liabilities [Abstract]
Net operating loss carry-forwards	$ 24,308,000	$ 19,900,000
Stock based compensation	6,862,000	4,800,000
Valuation allowance	(31,170,000)	(24,700,000)
Net non-current deferred tax asset	$ 0	$ 0

SUBSEQUENT EVENTS (Details)

SUBSEQUENT EVENTS (Details)

Mar. 30, 2022$ / sharesshares

Mar. 21, 2022USD ($)$ / sharesshares

Mar. 15, 2022$ / sharesshares

Feb. 17, 2022$ / sharesshares

Feb. 15, 2022shares

Feb. 07, 2022$ / sharesshares

Feb. 01, 2022USD ($)shares

Jan. 27, 2022USD ($)shares

Jan. 04, 2022shares

Jan. 03, 2022USD ($)shares

Dec. 28, 2021$ / sharesshares

Dec. 15, 2021$ / sharesshares

Oct. 21, 2021$ / sharesshares

Oct. 04, 2021shares

Sep. 17, 2021$ / sharesshares

Aug. 31, 2021$ / sharesshares

Aug. 14, 2021shares

Aug. 03, 2021$ / sharesshares

Jun. 30, 2021USD ($)

Jun. 01, 2021USD ($)

May 18, 2021$ / sharesshares

Apr. 13, 2021$ / sharesshares

Apr. 09, 2021$ / sharesshares

Mar. 08, 2021shares

Feb. 16, 2021$ / sharesshares

Jan. 21, 2021$ / sharesshares

Jan. 04, 2021shares

Oct. 09, 2020$ / sharesshares

Aug. 26, 2020

Jul. 13, 2020shares

Jun. 24, 2020shares

May 20, 2020$ / sharesshares

Apr. 14, 2020$ / sharesshares

Mar. 30, 2020shares

Mar. 25, 2020shares

Mar. 24, 2020

Feb. 25, 2020shares

Sep. 24, 2019

Mar. 31, 2022USD ($)shares

Feb. 16, 2021$ / sharesshares

Jan. 31, 2021USD ($)shares

Dec. 31, 2020$ / sharesshares

Dec. 31, 2020$ / sharesshares

Dec. 31, 2021USD ($)shares

Dec. 31, 2020USD ($)$ / sharesshares

Dec. 12, 2021$ / shares

Nov. 20, 2019$ / shares

SUBSEQUENT EVENTS (Details) [Line Items]

Stock Issued During Period, Shares, New Issues

2,187,500

1,068,550

2,500,000

251,720

83,055

424,357

Class of Warrant or Rights, Granted

6,575

125,000

125,000

Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share) | $ / shares

$ 10

$ 3.75

$ 3.75

$ 3.75

$ 2.27

$ 6.16

Proceeds from Issuance or Sale of Equity (in Dollars) | $

$ 10,300,000

Stock Issued During Period, Shares, Issued for Services

658,868

Stock Issued During Period, Value, Issued for Services (in Dollars) | $

$ 2,658,224

$ 3,975,000

$ 4,400,000

Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Granted

82,716

960,000

338,000

Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights

one-third vesting on the first anniversary of the date of grant, and the remaining two-thirds vesting in substantially equal quarterly installments over the following two years

one-third vesting on the first anniversary of the date of grant, and the remaining two-thirds vesting in substantially equal quarterly installments over the following two years

with half immediate vesting and half vesting on September 20, 2022

one-third vesting on the first anniversary of the date of grant, and the remaining two-thirds vesting in substantially equal quarterly installments over the following two years

one-third vesting on the first anniversary of the date of grant, and the remaining two-thirds vesting in substantially equal quarterly installments over the following two years

one-third vesting on the one-year anniversary and two-thirds vesting quarterly thereafter beginning May 18, 2022 for two years

one-third vesting on the one-year anniversary and two-thirds vesting quarterly thereafter beginning April 13, 2022 for two years

one-third vesting on the one-year anniversary and two-thirds vesting quarterly thereafter beginning April 9, 2022 for two years

one-third vesting on the one year anniversary and two-thirds vesting quarterly thereafter beginning February 16, 2022 for two years

one-third vesting on the one-year anniversary and two-thirds vesting quarterly thereafter beginning January 12, 2022 for two years

one-third vesting on the one year anniversary and two-thirds vesting quarterly thereafter beginning January 9, 2022 for two years.

one-third vesting on the one year anniversary and two-thirds vesting quarterly thereafter beginning November 26, 2021 for two years

one

40,000 fully vested and exercisable at the date of grant and 25,000 options vesting quarterly over three years

320,000 vesting immediately, and 640,000 vesting upon ViralClear meeting certain milestones

25,000 vesting immediately and 75,000 quarterly vesting beginning June 30, 2020 for two years

Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value (in Dollars) | $

$ 232,375

$ 109,725

Stock Issued During Period, Shares, Restricted Stock Award, Gross

219,334

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures

425,000

351,000

50,000

50,000

40,000

47,500

75,000

150,000

25,000

90,000

102,000

387,500

105,000

625,000

Share-based Compensation Arrangement by Share-basd Payment Award, Options, Exercise Price (in Dollars per share) | $ / shares

$ 2.44

$ 2.58

$ 2.89

$ 2.99

$ 2.98

$ 3.61

$ 3.2

$ 4.42

$ 4.38

$ 4.97

$ 4.23

$ 5.03

$ 10.49

$ 4.66

$ 4.97

Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period

10 years

10 years

10 years

10 years

10 years

10 years

10 years

10 years

10 years

10 years

10 years

10 years

10 years

10 years

10 years

10 years

Number of Employees

2

2

3

3

3

Subsequent Event [Member]

SUBSEQUENT EVENTS (Details) [Line Items]

Stock Issued During Period, Shares, Issued for Services

50,000

40,000

75,000

Stock Issued During Period, Value, Issued for Services (in Dollars) | $

$ 70,000

$ 72,800

$ 167,250

Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights

vesting in equal quarterly installments over one year

(i) 100,000 options vesting in equal quarterly installments over one year, and (ii) 150,000 options vesting 50% at grant date and 50% upon milestone of $7 million revenue

vests quarterly over one year

Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value (in Dollars) | $

$ 56,750

Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures

12,500

Stock Issued During Period, Shares, Restricted Stock Award, Gross

12,500

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures

350,000

30,000

250,000

Share-based Compensation Arrangement by Share-basd Payment Award, Options, Exercise Price (in Dollars per share) | $ / shares

$ 1.3

$ 1.58

$ 1.72

Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period

10 years

10 years

10 years

Number of Employees

3

Purchase Agreement [Member] | Subsequent Event [Member]

SUBSEQUENT EVENTS (Details) [Line Items]

Stock Issued During Period, Shares, New Issues

2,613,130

Shares Issued, Price Per Share (in Dollars per share) | $ / shares

$ 1.15

Class of Warrant or Rights, Granted

2,613,130

Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share) | $ / shares

$ 1.4

Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period

6 months

Proceeds from Issuance or Sale of Equity (in Dollars) | $

$ 3,000,000

Employees [Member]

SUBSEQUENT EVENTS (Details) [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period

3 years

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures

90,000

Share-based Compensation Arrangement by Share-basd Payment Award, Options, Exercise Price (in Dollars per share) | $ / shares

$ 4.66

Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period

10 years

Employees [Member] | Subsequent Event [Member]

SUBSEQUENT EVENTS (Details) [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights

one-third vesting on the first anniversary of the date of grant, and the remaining two-thirds vesting in substantially equal quarterly installments over the following two years

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures

36,000

Share-based Compensation Arrangement by Share-basd Payment Award, Options, Exercise Price (in Dollars per share) | $ / shares

$ 1.58

Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period

10 years

Number of Employees

2

Restricted Stock Units (RSUs) [Member]

SUBSEQUENT EVENTS (Details) [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Granted

31,000

220,000

301,000

175,000

Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights

vesting quarterly for one year

105,000 vesting one-third on the one-year anniversary and two-thirds vesting quarterly thereafter beginning January 4, 2022 for two years and with 115,000 vesting quarterly for one year

Stock Issued During Period, Shares, Restricted Stock Award, Gross

50,000

Restricted Stock Units (RSUs) [Member] | Subsequent Event [Member]

SUBSEQUENT EVENTS (Details) [Line Items]

Stock Issued During Period, Shares, Conversion of Convertible Securities

53,749

Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Granted

25,000

Restricted Stock [Member]

SUBSEQUENT EVENTS (Details) [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Granted

40,000

1,380,716

Restricted Stock [Member] | Subsequent Event [Member]

SUBSEQUENT EVENTS (Details) [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Granted

25,000

Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights

12,500 shares vesting immediately and 12,500 shares vesting upon completion of certain milestones

Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value (in Dollars) | $

$ 56,750

Share-based Payment Arrangement, Option [Member] | Subsequent Event [Member]

SUBSEQUENT EVENTS (Details) [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights

one-third vesting on the first anniversary of the date of grant, and the remaining two-thirds vesting in substantially equal quarterly installments over the following two years

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures

70,000

Share-based Compensation Arrangement by Share-basd Payment Award, Options, Exercise Price (in Dollars per share) | $ / shares

$ 1.28

Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period

10 years